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Adherence to combination antiretroviral therapy is important for achieving 
optimal HIV-related outcomes.  Epidemiologic data indicate that persons with mental 
disorders are disproportionately affected by HIV/AIDS, which is concerning since having 
a mental disorder has been associated with poor adherence to medications for treatment 
of chronic disease states.  The purpose of this study was to examine the relationship 
between the presence of mental disorders and adherence to combination antiretroviral 
therapy.  Additionally, this study examined the relationship between adherence to 
psychotropic medications and adherence to antiretroviral therapy.   
Study data were collected from the Texas Medicaid Vendor Drug Program 
database and Texas Medicaid enrollment files.  Adherence to and persistence with 
antiretroviral therapy, as well as adherence to psychotropic medications when applicable, 
were evaluated over a 12-month period in 1,321 patients starting a new combination 
antiretroviral regimen.  The presence of a mental disorder was defined based on 
 vii
prescription claims for psychotropic medications.  Proportion of days covered was used 
to calculate adherence, while persistence was defined as the number of days persistent 
with all antiretrovirals in the index regimen.  Logistic regression was used to evaluate the 
relationship between psychotropic medication use and adherence to antiretroviral therapy 
(90% cut-off), as well as the relationship between adherence to psychotropic medications 
(80% cut-off) and adherence to antiretroviral therapy.  The relationship between 
antiretroviral persistence and psychotropic medication use was evaluated using multiple 
linear regression.  Factorial ANOVA was used to evaluate the interactions between 
race/ethnicity, gender, and psychotropic medication use in their effects on adherence to 
and persistence with antiretroviral therapy. 
No significant relationship was found between the presence of a mental disorder 
and adherence to or persistence with combination antiretroviral therapy in this study.  
However, the limitations of using psychotropic medication use as a proxy for mental 
disorders may have affected the results.  Adherence to psychotropic medications overall 
(n = 501; OR = 3.37, 95% CI: 1.86 – 6.10; p < 0.001) and specifically to antidepressants 
(n = 443; OR = 4.23, 95% CI: 2.31 – 7.75; p < 0.001) was significantly associated with 
adherence to antiretroviral therapy, indicating a possible relationship between effective 
treatment for mental disorders and combination antiretroviral therapy adherence.  While 
additional research is needed to clarify this relationship, these data support the need for 
an integrated approach to treatment of mental disorders and HIV/AIDS. 
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Introduction and Literature Review 
BACKGROUND 
Human Immunodeficiency Virus (HIV) infection and the associated Acquired 
Immune Deficiency Syndrome (AIDS) continue to be a significant health issue both 
in the United States as a whole and in the state of Texas.  At the end of 2006, an 
estimated 491,727 persons in the U.S. were living with HIV/AIDS, of which 59,066 
(12.0%) were estimated to be from Texas.1  While the incidence of HIV/AIDS in the 
U.S. remained stable from 2003-2006, HIV/AIDS prevalence increased steadily as 
the number of deaths of persons with AIDS decreased.1 
Epidemiologic data indicate that racial and ethnic minorities are 
disproportionately affected by HIV/AIDS (Table 1.1).  In 2006, rates of HIV/AIDS in 
the U.S. black and Hispanic populations were 67.7 per 100,000 and 25.5 per 100,000, 
respectively, as compared to 8.2 per 100,000 in the white population.1  Although 
blacks represent only about 13% of the U.S. population, they accounted for 49% of 
all HIV/AIDS cases diagnosed in 2006.1,2  A similar trend is seen in Texas, where 
blacks represent 11% of the population but accounted for 38% of all the HIV/AIDS 
cases in 2006.3  The rate for blacks living with HIV/AIDS in Texas in 2006 was over 
four times higher than the rate for whites and Hispanics (Figure 1.1).3  Rates of 
HIV/AIDS are higher among males than females across  all racial/ethnic groups, 
though women of racial/ethnic minorities may be particularly at risk.  The rate of new 
HIV/AIDS diagnoses in black females in Texas was nine times higher than the rate in 
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Hispanic females and 19 times higher than the rate in white females in 2006 (Figure 
1.2).3 
As with racial and ethnic minorities, rates of HIV/AIDS are disproportionately 
high among persons with mental disorders.  This is important to consider since data 
from a recent, nationally representative survey indicates that the prevalence of serious 
mental disorders in the U.S. over a 12-month period is approximately 6.5%.4  
Multiple studies have shown that persons suffering from serious mental disorders are 
at an increased risk for contracting HIV as compared to the general population, with 
the degree of risk varying by geographic region.5-7  In a review of studies published 
through 1996 that evaluated the prevalence of HIV infection among persons with 
serious mental disorders, the overall seroprevalence was found to be 7.8%, which is 
much higher than the estimated 0.4% prevalence in the general U.S. population at that 
time.5  After controlling for age, sex, race/ethnicity, and time spent on welfare, one 
study of Medicaid recipients found that patients with a schizophrenia spectrum 
disorder were 1.5 times more likely than those without a serious mental disorder to be 
diagnosed with HIV infection, whereas patients with a major affective disorder were 
3.8 times as likely.7  Possible explanations for the increased risk of HIV infection 
among those with mental disorders include the greater likelihood that persons with 
mental disorders will engage in high-risk sexual behaviors (e.g., multiple sexual 
partners, infrequent condom use, trading sex for money or drugs) and the higher 
prevalence of substance use, including injection drug use, in this population.5-8   
The influence of race/ethnicity and gender on the rates of HIV infection 
among persons with serious mental disorders has not been clearly defined, though 
there is some evidence to suggest that these relationships may differ from those seen 
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in the general population.  As discussed above, the rate of HIV/AIDS in the U.S. 
black population is higher than that in the white and Hispanic populations.1  When 
combining data from studies published through 1996 that evaluated the prevalence of 
HIV infection among persons with serious mental disorders, rates of seropositivity 
were similarly higher among blacks and Hispanics as compared to whites.5  In the 
general U.S. population, the rate of HIV/AIDS is higher among men than women, 
with a ratio of approximately 3:1.1  In contrast, studies evaluating the rate of HIV 
infection among persons with serious mental disorders have found near equality in the 
rates of HIV by sex.5,6  This indicates that women with serious mental disorders may 











Table 1.1 Estimated Numbers of Cases and Rates (per 100,000 population) of 
HIV/AIDS in Adults and Adolescents by Race/Ethnicity and Sex in 33 
States with Confidential Name-Based HIV Infection Reporting, 2006a 
 Males Females Totalb 
Race/Ethnicity No. Rate No. Rate No. Rate 
White, not Hispanic 9,078 16.7 1,664 2.9 10,742 9.6
Black, not Hispanic 11,230 119.1 6,033 56.2 17,263 85.6
Hispanic 5,058 50.9 1,400 15.1 6,458 33.7
Asian/Pacific Islander 318 13.5 79 3.2 397 8.2
American Indian/Alaska Native 129 17.7 35 4.6 164 11.0
Totalc 25,928 33.8 9,252 11.5 35,180 22.4
a Adapted from: Centers for Disease Control and Prevention. HIV/AIDS Surveillance 
Report, 2006. Vol. 18. Atlanta, GA: U.S. Department of Health and Human Services, 
Centers for Disease Control and Prevention;2008:5-10,24. Available at: 
http://www.cdc.gov/hiv/topics/surveillance/resources/reports/. Accessed: May 12, 
2008. 
bBecause row totals were calculated independently of the values for the 
subpopulations, the values in each row may not sum to the row total. 
c Includes persons of unknown race or multiple races. Because column totals were 
calculated independently of the values for the subpopulations, the values in each 









Figure 1.1 Number and Rate (per 100,000 population) of Persons Living with 
HIV/AIDS by Race/Ethnicity, Texas, 2002-2006a 
 
a Texas Integrated Epidemiologic Profile for HIV/AIDS Services Planning, January 
2008. HIV/STD Epidemiology and Surveillance Branch of the Texas Department of 
State Health Services;2008:6-12. Available at: http://www.dshs.state.tx.us/hivstd/ 








Figure 1.2 Number and Rate (per 100,000 population) of New Diagnoses by Sex and 
Race/Ethnicity, Texas, 2006a 
 
a Texas Integrated Epidemiologic Profile for HIV/AIDS Services Planning, January 
2008. HIV/STD Epidemiology and Surveillance Branch of the Texas Department of 
State Health Services;2008:6-12. Available at: http://www.dshs.state.tx.us/hivstd/ 
planning/Epi_Profile_02012008.pdf.  Accessed: May 12, 2008. 
 
 
OVERVIEW OF ANTIRETROVIRAL THERAPY AND ADHERENCE 
Antiretroviral therapy for treatment of HIV-infection has progressed 
significantly since the introduction of zidovudine (AZT) in March 1987.  Use of 
potent combination antiretroviral therapy as the standard of care has led to substantial 
improvements in survival among patients diagnosed with AIDS.9  Despite major 
advances in treatment, currently available combination antiretroviral regimens will 
not lead to eradication of the HIV virus.  Therefore, the Department of Health and 
Human Services recommended goals of antiretroviral treatment focus on prolonging 
 7
survival and improving quality of life through restoring and preserving immunologic 
function and “maximally and durably” suppressing viral load.10 
All currently recommended combination antiretroviral regimens consist of at 
least three drugs active against the HIV virus.  Although six mechanistic classes of 
antiretroviral agents are available for inclusion in combination antiretroviral 
regimens, several regimens are preferred for initial therapy based on evidence for 
their efficacy and tolerability (Table 1.2).10  The combination antiretroviral regimen 
that is chosen should be tailored to the individual patient based on factors such as 
potential side effects, pill burden, comorbid conditions, interactions with required 
medications, and results of drug resistance testing.10 
Adherence refers to the extent to which patients take their medications as 
prescribed.  Multiple factors are associated with decreased medication adherence, 
including patient forgetfulness, misunderstanding of dosing instructions, high side 
effect burden, complexity of regimen, poor patient-prescriber relationship, high 
medication cost, and indication for a chronic versus an acute condition.11  Adherence 
to antiretroviral therapy is complicated by the fact that all recommended regimens 
consist of multiple medications, many of which are expensive.11  All of these 
medications are associated with side effects (e.g. gastrointestinal symptoms and 
lipodystrophy with protease inhibitors and central nervous system effects with 
efavirenz), which could reduce patients’ willingness to adhere to therapy.10  
Additionally, the stigma associated with HIV infection may foster nonadherence 
when patients are concerned that others will see them taking their medications.12  
Once the decision is made to initiate antiretroviral therapy, treatment must be 
maintained for a lifetime, requiring the patient to make a life long commitment to 
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antiretroviral adherence.10  Earlier combination antiretroviral therapy regimens were 
associated with a high pill burden, multiple daily dosing, and food requirements that 
made adherence difficult.  In an effort to ease adherence, coformulations of 
antiretroviral agents have been developed to reduce pill burden, and studies have been 
conducted to establish the efficacy of once daily administration for some agents.12  
The recently developed coformulation of efavirenz/emtricitabine/tenofovir allows 
patients to receive a complete combination antiretroviral therapy regimen in only one 
pill taken once daily.  Despite the significant simplification of many antiretroviral 
regimens, patient education regarding HIV infection, potential medication side 
effects, and the consequences of nonadherence will still be essential for optimizing 










Table 1.2 Antiretroviral Components Recommended for Treatment of HIV-1 
Infections in Treatment-Naïve Patientsa 
Select an NNRTI or PI to Add to a Dual-NRTI Backbone 









PI: atazanavir + ritonavir, 















PI: atazanavir, fosamprenavir, 
fosamprenavir + ritonavir, 
lopinavir/ritonavir (1x/day), 





didanosine + (emtracitabine or 
lamivudine) 
Abbreviations: NNRTI = nonnucleoside reverse transcriptase inhibitor; PI = protease inhibitor;    
NRTI = nucleoside reverse transcriptase inhibitor
aAdapted from: Guidelines for the use of antiretroviral agents in HIV-1-infected 
adults and adolescents. 1 December 2007. The Panel of Clinical Practices for the 
Treatment of HIV Infection convened by the Department of Health and Human 
Services. Available at: http://AIDSinfo.nih.gov. Accessed: March 13, 2008. 
bEmtricitabine may be used in place of lamivudine and vice versa. 
 
ADHERENCE TO ANTIRETROVIRAL THERAPY AND HIV-RELATED OUTCOMES 
Adherence is a chief concern with lifelong combination antiretroviral therapy, 
since high rates of adherence have been correlated with HIV viral suppression, 
reduced viral resistance, and improved patient survival.10  It is widely accepted that at 
least 95% adherence to antiretroviral therapy is required to achieve virologic 
suppression, a figure that is based on linking medication adherence to disease 
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outcomes with unboosted protease inhibitor (PI)-based regimens.  Paterson and 
colleagues evaluated the relationship between adherence to protease inhibitors and 
patient outcomes in 99 HIV-infected outpatients recruited from clinics in Pittsburgh, 
PA and Omaha, NE.13  Both patients who were already receiving a protease inhibitor 
at baseline and patients who were to be newly initiated on a protease inhibitor were 
included in this study.  Adherence was measured prospectively using the Medication 
Event Monitoring System (MEMS), with a median duration of follow-up of 6 months.  
Decreased adherence was significantly associated with risk for virologic failure (p < 
0.001), which was defined as an HIV RNA level greater than 400 copies/mL at the 
last study visit (Figure 1.3).  Only 5 of 23 (22%) patients with 95% or greater 
adherence experienced virologic failure, whereas the risk of virologic failure was 
61% in patients with 80-94.9% adherence (odds ratio = 5.6, 95% CI: 1.3 – 25.7) and 
80% in patients with less than 80% adherence (odds ratio = 14.4, 95% CI: 3.4 – 66.6).  
Changes in CD4 lymphocyte count were also significantly related to degree of 
adherence (p = 0.006).  The mean increase in CD4 lymphocyte count from baseline to 
final study visit was significantly greater for patients with 95% or greater adherence 
(83 cells/mm3) than those with less than 95% adherence (6 cells/mm3, p = 0.045).  
Based on these data, the authors concluded that adherence of 95% or greater to 
protease inhibitors is necessary for optimal virologic outcomes. 
More recent studies indicate that non-nucleoside reverse transcriptase 
inhibitor (NNRTI)-based regimens and ritonavir-boosted PI-based regimens may 
achieve acceptable viral load suppression at rates of adherence lower than 95%.14-16  
Using data collected prospectively from a cohort of homeless and marginally housed 
persons living in San Francisco, California, Bangsberg and colleagues found that viral 
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load suppression (HIV RNA < 400 copies/mL) was significantly more common for 
patients newly started on NNRTI-based regimens than those started on unboosted 
protease inhibitor regimens (p = 0.001).14  Patients were followed for a median of 9.1 
months and adherence was determined using unannounced pill counts.  When 
adherence was divided into quartiles based on unannounced pill count determinations, 
the majority of patients receiving NNRTI-based therapy achieved viral load 
suppression at adherence levels of 54-100%.  Nachega and colleagues evaluated the 
relationship between adherence to NNRTI-based antiretroviral therapy and viral load 
suppression in a large cohort of previously treatment-naïve patients enrolled in an 
HIV/AIDS disease management program in South Africa.15  Adherence was 
calculated based on prescription drug claims.  The primary outcome in this study was 
sustained viral load suppression, which was defined as an HIV RNA level < 400 
copies/mL at all measurements from one month after antiretroviral therapy initiation 
to end of follow-up (median follow-up period was 2.2 years).  The authors found that 
rates of adherence greater than or equal to 80% were associated with sustained viral 
load suppression in the majority of patients.  However, it was also found that every 
10% increase in adherence beyond 50% was associated with a mean absolute increase 
of 0.10 in the proportion of patients achieving sustained viral load suppression, 
indicating a dose-response relationship between adherence and viral suppression. 
The relationship between adherence to ritonavir-boosted PI regimens and 
virologic suppression was evaluated by Shuter and colleagues.16  Sixty-four HIV-
infected outpatients taking an antiretroviral regimen containing lopinavir/ritonavir 
were recruited from a clinic in the Bronx, NY.  Adherence was evaluated 
prospectively using MEMS over the 24-week study period.  The results of this study 
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did not reveal a strong relationship between antiretroviral adherence and virologic 
suppression, as no significant difference was found in the proportion of patients who 
achieved virologic suppression (HIV RNA < 400 copies/mL) among the 
lopinavir/ritonavir adherence quartiles (p = 0.42).  Rates of virologic suppression in 
this study were high, and even at the lowest level of adherence (23.5-53.3%), 69% of 
patients achieved a viral load of < 400 copies/mL at 24 weeks. 
Although recent evidence suggests that some combination antiretroviral 
regimens may not require at least 95% adherence for most patients to achieve viral 
load suppression, efforts should still be made to maximize antiretroviral adherence in 
order to achieve the goal of maximum and durable suppression of viral load.10  This is 
emphasized by the finding of Nachega and colleagues that there is a dose-response 
relationship between viral load suppression and antiretroviral adherence.15  
Additionally, nonadherence to antiretroviral therapy has important public health 
implications, as suboptimal adherence has been linked to the development of HIV 











Figure 1.3 Adherence to Unboosted Protease Inhibitor Therapy and Virologic Failurea 
   
a Paterson DL, Swindells S, Mohr J, et al. Adherence to protease inhibitor therapy and 
outcomes in patients with HIV infection. Ann Intern Med 2000;133:21-30. 
 
TREATMENT ADHERENCE AND MENTAL DISORDERS 
As discussed above, multiple factors may engender nonadherence to 
combination antiretroviral therapy, including cost, side effects, and chronicity of 
treatment.  While these factors present barriers to antiretroviral adherence for any 
population, they may be particularly difficult to overcome for patients with mental 
disorders, who often suffer from cognitive impairment and behavioral instability.  
Patients with serious mental disorders, including depression, bipolar disorder, and 
schizophrenia, often have poor adherence with psychotropic medications.18-21  
Additionally, having a mental disorder has been associated with poor adherence to 
medications used to treat chronic medical conditions, including diabetes, 
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hypertension, and coronary heart disease.22-25  It is not surprising, therefore, that 
several studies have found an association between the presence of mental disorders 
and poor adherence to antiretroviral therapy.13,27-30 
In the previously described study by Paterson and colleagues, which evaluated 
the relationship between adherence to unboosted PI-based therapy and HIV-related 
outcomes, factors associated with improved adherence were also assessed.13  
Psychiatric comorbidity was evaluated at baseline using the General Health 
Questionnaire, a 28-item measure divided into four subscales of psychiatric 
symptoms: somatic symptoms, anxiety and insomnia, social dysfunction, and 
depression.26  Lower psychiatric comorbidity as measured by the General Health 
Questionnaire was associated with greater than or equal to 95% adherence to 
antiretroviral medication (p = 0.0014), and remained a significant predictor of  at least 
95% adherence after adjustment for other demographic and disease state factors 
associated with adherence (odds ratio = 1.7, p = 0.04, 95% CI: 1.0 – 3.0).13   
In a two week prospective study, Wagner and colleagues evaluated adherence 
to antiretroviral therapy among 47 Los Angeles, CA residents with serious mental 
disorders using an electronic monitoring cap system.27  Patients included in this study 
were diagnosed with bipolar depression (51%), schizophrenia (26%), schizoaffective 
disorder (11%), and major depression with psychotic features (13%).  Most (91%) 
patients were using antiretroviral regimens with a twice-daily dosing schedule, and 
the average time on the current antiretroviral regimen was 29 months.  Even during 
the brief, 2-week observation period, less than half of participants (40%) 
demonstrated at least 90% adherence, and 31% of patients had less than 50% 
adherence.  Although not statistically significant, the rates of adherence in this study 
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varied by psychiatric diagnosis.  The mean rate of adherence was 81% for patients 
with schizoaffective disorder, 70% for patients with bipolar depression, 59% for 
patients with schizophrenia, and 52% for those who had major depression with 
psychotic features. 
Tucker and colleagues analyzed data from the HIV Cost and Services 
Utilization Study to evaluate the effects of specific psychiatric disorders on adherence 
to antiretroviral medication.28  The HIV Cost and Services Utilization Study was a 
probability sample of 2,864 HIV-infected patients who were representative of all the 
adult HIV-infected patients living in the contiguous United States in early 1996.  
Study data were collected from a baseline and two follow-up interviews.  The 
analyses in this study were based on data from 1,910 patients who participated in all 
three interviews and who were taking antiretroviral medications at the time of the 
second follow-up interview.  Antiretroviral adherence was determined by patient 
responses to interview questions about pill-taking behavior at the time of the second 
follow-up.  Patients were considered to be nonadherent if they reported any 
deviations from the prescribed regimen over the past week.  General mental health 
status at the time of the second follow-up was evaluated using the five-item Mental 
Health Index from the 36-item Short Form (SF-36) Health Survey, which evaluates 
anxiety, depression, loss of behavioral or emotional control, and psychological well-
being over the past month.  Patients were identified as having a probable diagnosis of 
depression, dysthymia, generalized anxiety disorder (GAD), or panic disorder based 
on responses to the Short-Form of the World Health Organization Composite 
International Diagnostic Interview during the first follow-up interview.   
 16
Nineteen percent of patients in this sample had evidence for a probable 
psychiatric disorder, with major depression being the most common (16.5%).28  After 
adjustment for important demographic and disease state variables, having a probable 
diagnosis of depression (odds ratio = 1.7,  p = 0.001, 95% CI: 1.3 – 2.3], GAD (odds 
ratio = 2.4, p = 0.02, 95% CI: 1.2 – 5.0), or panic disorder (odds ratio = 2.0, p < 
0.001, 95% CI: 1.4 – 3.0) increased the likelihood of patient-reported nonadherence 
to antiretroviral medication.  Even after adjustment for self-reported substance use, 
poorer general mental health (odds ratio = 1.3, p = 0.02, 95% CI: 1.0 – 1.6) and 
probable diagnosis of a psychiatric disorder (odds ratio = 1.7, p = 0.002, 95% CI:   
1.2 – 2.3) remained significantly associated with nonadherence. 
In an Italian study conducted by Ammassari and colleagues, the effects of 
depressive symptoms and cognitive impairment on adherence to antiretroviral therapy 
were assessed in 135 HIV-infected patients.29  Adherence to antiretroviral 
medications was assessed by asking patients about the timing of their last missed dose 
in the previous four weeks.  Patients who reported missing a dose of medication in the 
previous week were considered to be nonadherent.  Depressive symptoms were rated 
using the Montgomery-Åsberg Depression Rating Scale (MADRS), and patients were 
considered to have prominent depressive symptoms if their MADRS score was 
greater than 19.  Cognitive impairment was assessed by a battery of 
neuropsychological tests and defined as performance of 1.5 or more standard 
deviations below published age-matched norms.  Patients in this study had been 
taking their current antiretroviral regimen for less than one year, on average.  The rate 
of self-reported nonadherence was 30%.  Thirty-two (24%) patients were found to 
have prominent depressive symptoms and 16 (12%) were found to have global 
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neurocognitive impairment.  The presence of prominent depressive symptoms was 
associated with an increased likelihood for antiretroviral nonadherence (odds ratio = 
3.12, p = 0.008, 95% CI: 1.36 – 7.13), though global cognitive impairment was not.  
The relationship between depressive symptoms and nonadherence was weakened but 
remained significant (odds ratio = 1.05, p = 0.03, 95% CI: 1.00 – 1.10) after 
adjustment for other variables associated with nonadherence. 
In addition to its impact on adherence, the presence of mental disorders may 
affect persistence with antiretroviral therapy.  Walkup and colleagues utilized data 
from 2,459 HIV-infected New Jersey Medicaid beneficiaries to evaluate the use of 
newer PI and NNRTI-based antiretroviral regimens among patients with serious 
mental disorders.30  Persistence with these regimens was included as a secondary 
outcome.  Diagnosis of a serious mental disorder was determined based on service 
claims including International Classification of Diseases, 9th Revision, Clinical 
Modification (ICD-9-CM) codes for schizophrenia, bipolar disorder, or major 
depressive disorder, recurrent episode.  Patients with ICD-9-CM codes for bipolar 
disorder or major depressive disorder, recurrent episode were considered to have a 
severe affective disorder.  Persistence with antiretroviral therapy was analyzed by 
examining quarterly use of PIs or NNRTIs among participants.  The use of PI and 
NNRTI-based antiretroviral regimens was found to be higher among patients with 
schizophrenia (68.3%) and severe affective disorders (75.6%) than patients without 
serious mental disorders (64.3%, p = 0.003).  After controlling for demographic and 
disease state factors, patients with severe affective disorders (odds ratio = 0.73, p < 
0.01, 95% CI: 0.57 – 0.94), but not those with schizophrenia (odds ratio = 1.04,    p = 
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NS, 95% CI: 0.78 – 1.38), were less likely to be persistent with antiretroviral therapy 
than those with no serious mental disorders. 
 
PSYCHOTROPIC MEDICATION ADHERENCE AND ADHERENCE TO 
ANTIRETROVIRAL THERAPY 
The association of mental disorders, particularly affective disorders, with an 
increased risk of nonadherence to antiretroviral therapy is supported by several 
studies using varying definitions of mental disorders and adherence.  Symptoms of 
mental disorders are potentially modifiable risk factors for nonadherence.  It is 
therefore important to know whether appropriate treatment of mental disorders leads 
to improved adherence to antiretroviral therapy.  Relatively few studies have 
addressed this issue, and most analyses have focused on the use of antidepressants.   
In the study by Wagner and colleagues discussed above, which prospectively 
evaluated adherence to antiretroviral therapy among patients with serious mental 
disorders, self-reported adherence to psychotropic medication was associated with 
adherence to antiretroviral therapy.27  Thirty-six of the 47 patients (77%) included in 
the study were taking psychotropic medication, with antidepressants being the most 
commonly used agents (62%).  Mood stabilizers and antipsychotics were each used 
by 26% of the sample and anxiolytics were used by 15%.  Adherence to psychotropic 
medication was assessed at study endpoint by asking patients to recall their pill-taking 
behavior over the past 3 days.  The mean self-reported adherence to psychotropic 
medications was 86%.  A moderate correlation was found between self-reported 
adherence to psychotropics and both self-reported (r = 0.45, p < 0.05) and 
electronically monitored (r = 0.45, p < 0.05) adherence to antiretroviral therapy. 
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Yun and colleagues performed a retrospective cohort study to evaluate the 
effect of antidepressant treatment on antiretroviral adherence in HIV-infected patients 
with comorbid depression.31  A cohort of 1,713 primarily indigent HIV-infected 
patients was identified using surveillance data from the Denver Public Health 
Department that was previously collected for other studies.  Patients were considered 
to be depressed if administrative data contained an ICD-9 code for Major Depressive 
Disorder or for Bipolar I Disorder with the most recent episode depressed or mixed.  
Patients were also considered to have depression if a provider assessment of 
depression was documented in the patient’s medical chart, or if electronic pharmacy 
records revealed treatment with antidepressants.  Patients receiving only low doses of 
tricyclic antidepressants or trazodone were not considered to have depression.  
Adherence to antiretroviral and antidepressant medications was calculated based on 
outpatient electronic pharmacy records.  System-wide pharmacy data were likely to 
account for most prescriptions received by study participants, as AIDS Drug 
Assistance Program medications were provided to patients at a significantly reduced 
cost.  Adherence to antiretroviral therapy was calculated by adding the number of 
days dispensed for each antiretroviral drug used during the study period and dividing 
by the sum of the observation periods (time from first to last refill plus number of 
days dispensed) for each drug; a similar calculation was used to determine 
antidepressant adherence.  Patients were considered to be adherent to antiretroviral 
therapy if the calculated adherence rate was at least 95%.  Patients with a calculated 
adherence rate greater than or equal to the median adherence value for antidepressant 
medications were considered to be adherent to antidepressants. 
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Of the 1,713 HIV-infected patients identified, 818 (48%) received 
antiretroviral therapy, with a mean adherence rate of 72%.31  Nine-hundred eighty-
one patients (57%) were considered to have a diagnosis of depression, of which 450 
(46%) were prescribed antidepressants (median adherence rate 87%).  While the 
authors originally concluded that both receipt of and adherence to antidepressant 
treatment was associated with antiretroviral adherence, a subsequently published 
commentary by peers led the authors to reevaluate their analyses.32  The proportion of 
depressed patients who received antidepressant therapy was lower among those who 
were at least 95% adherent to antiretroviral therapy, which may indicate that merely 
prescribing antidepressant therapy does not improve antiretroviral adherence among 
depressed patients.  However, when adherence to antidepressant therapy was taken 
into account, the proportion of depressed patients who received and were adherent to 
antidepressant therapy was higher among those who were adherent to antiretroviral 
therapy (69%) than those who were not (48%; odds ratio = 2.45, p = 0.001, 95% CI: 
1.39 – 4.29). 
In another large retrospective cohort study, Horberg and colleagues evaluated 
the effects of depression and selective serotonin reuptake inhibitor (SSRI) use on 
antiretroviral adherence.33  Data from two large health maintenance organizations 
were used to identify a cohort of 3,359 HIV-infected individuals initiated on a new 
combination antiretroviral regimen (either newly initiated or switched from a 
previous regimen).  Patients were considered to be depressed if they had at least one 
outpatient visit with a coded clinical diagnosis of depression, major depression, or 
dysthymia.  Adherence to antiretroviral therapy and SSRIs over the 12-month 
observation period was calculated from pharmacy dispensing and refill data, with 
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antiretroviral adherence calculated across all antiretroviral medications.  The 
adherence measure used expressed the number of doses for which a patient had the 
drug in possession as a percentage of the total number of intended doses in the 
interval between the first and last refill.  Patients with a calculated adherence of 
greater than or equal to 90% were considered adherent to antiretroviral therapy, 
whereas adherence greater than 80% was considered sufficient for SSRIs. 
Of the 3,359 patients included in this study, 1,398 (42%) were diagnosed with 
depression and 508 (15%) were prescribed SSRIs.33  The overall mean rate of 
adherence to antiretroviral therapy was high at 80.9%.  The mean adherence to SSRIs 
over the 12-month observation period was 76.9%, and 57.9% of those prescribed 
SSRIs achieved greater than 80% adherence.  When adherence to antiretroviral 
therapy was treated as a continuous measure, rates of antiretroviral adherence were 
lower among patients with depression (81.4% for patients treated with SSRIs, 79.2% 
for patients not treated with SSRIs; p < 0.001 for both) than for nondepressed patients 
(82.6%).  While statistically significant, these small differences in antiretroviral 
adherence are unlikely to be clinically meaningful.  Patients who were greater than 
80% adherent to SSRIs had a higher mean rate of antiretroviral adherence (84.7%) 
than nondepressed patients (82.6%, p < 0.001) or depressed patients without exposure 
to SSRIs (79.2%, p = 0.001).  After adjustment for age, gender, antiretroviral-naïve 
status, antiretroviral regimen type, and temporal trend, rates of antiretroviral 
adherence among depressed patients without exposure to SSRIs remained 
significantly lower than that for nondepressed patients (p = 0.01), and patients who 
were greater than 80% adherent to SSRIs had significantly higher rates of 
antiretroviral adherence than depressed patients without exposure to SSRIs (p = 0.01).  
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When adherence was dichotomized based on achieving at least 90% adherence to 
antiretroviral therapy, depressed patients without SSRI exposure had significantly 
lower odds of achieving at least 90% adherence than nondepressed patients (adjusted 
odds ratio = 0.81, p = 0.03, 95% CI: 0.7 – 0.98).  Patients who were treated with 
SSRIs were just as likely as nondepressed patients to achieve at least 90% adherence 
to antiretroviral therapy (adjusted odds ratio = 0.91, p = 0.41, 95% CI: 0.72 – 1.15).  
Patients with greater than 80% adherence to SSRIs were no more likely than 
nondepressed patients to achieve at least 90% adherence to antiretrovirals (adjusted 
odds ratio = 1.13, p = 0.39, 95% CI: 0.86 – 1.49), though they were significantly 
more likely than depressed patients without SSRI exposure to achieve this level of 
adherence (p = 0.01). 
 
STUDY OBJECTIVES 
The purpose of the current study is to evaluate the relationship between 
mental disorders and patient adherence to antiretroviral therapy, with the intent to 
determine if certain subgroups of the population with mental disorders, based on 
race/ethnicity and gender, are particularly at risk for nonadherence.  This study will 
also evaluate the relationship between adherence to psychotropic medications and 
adherence to combination antiretroviral therapy to determine if efforts to improve 
antiretroviral adherence among patients with mental disorders should emphasize 
adherence to psychotropic medications.  Specific study objectives are: 1) to compare 
the prevalence of psychotropic medication use among subgroups of patients taking 
antiretroviral therapy based on race/ethnicity and gender; 2) to examine the 
relationship between psychotropic medication use and antiretroviral adherence and 
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persistence, taking into account race/ethnicity and gender; and 3) to examine the 
relationship between antiretroviral adherence and adherence to psychotropic 
medications while controlling for race/ethnicity, gender, antiretroviral regimen type, 
and total number of medications. 
 
Tested Hypotheses 
Objective One:  To compare the prevalence of psychotropic medication use among 
subgroups of patients taking antiretroviral therapy based on race/ethnicity and gender. 
 H01: There will be no significant difference in the prevalence of psychotropic 
medication use among HIV-infected patients based on race/ethnicity. 
 H02: There will be no significant difference in the prevalence of psychotropic 
medication use among HIV-infected patients based on gender. 
Rationale for H01 through H02: Previous studies indicate that the risk of contracting 
HIV is higher among patients with mental disorders.5-7  Some data suggest that, 
among patients with mental disorders, racial/ethnic minorities and women may be 
disproportionately affected by HIV/AIDS, though these relationships have not been 
clearly established.5,6 
 
Objective Two: To examine the relationship between psychotropic medication use 
and antiretroviral adherence and persistence, taking into account race/ethnicity and 
gender. 
 H03: There will be no significant difference in the rate of adherence to 
antiretroviral therapy between those with and those without psychotropic 
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medication use after controlling for race/ethnicity, gender, antiretroviral 
regimen type, and total number of medications. 
 H04: There will be no significant difference in the rate of adherence to 
antiretroviral therapy based on the interaction between psychotropic 
medication use and race/ethnicity. 
 H05: There will be no significant difference in the rate of adherence to 
antiretroviral therapy based on the interaction between psychotropic 
medication use and gender. 
 H06: There will be no significant difference in the rate of adherence to 
antiretroviral therapy based on the interaction between psychotropic 
medication use, race/ethnicity, and gender. 
 H07: There will be no significant difference in persistence with antiretroviral 
therapy between those with and those without psychotropic medication use 
after controlling for race/ethnicity, gender, antiretroviral regimen type, and 
total number of medications. 
 H08: There will be no significant difference in persistence with antiretroviral 
therapy based on the interaction between psychotropic medication use and 
race/ethnicity. 
 H09: There will be no significant difference in persistence with antiretroviral 
therapy based on the interaction between psychotropic medication use and 
gender. 
 H010: There will be no significant difference in persistence with antiretroviral 
therapy based on the interaction between psychotropic medication use, 
race/ethnicity, and gender. 
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Rationale for H03 through H010: Previous studies have indicated that having a mental 
disorder is associated with poor adherence to antiretroviral therapy but have not 
evaluated whether specific subgroups of patients with mental disorders are 
particularly at risk for nonadherence.13, 27-30 
 
Objective Three: To examine the relationship between antiretroviral adherence and 
adherence to psychotropic medications while controlling for race/ethnicity, gender, 
antiretroviral regimen type, and total number of medications. 
 H011: Among patients using psychotropic medications, there will be no 
significant relationship between adherence to antiretroviral therapy and 
adherence to psychotropic medications while controlling for race/ethnicity, 
gender, antiretroviral regimen type, and total number of medications. 
 H012: Among patients taking antidepressants, there will be no significant 
relationship between adherence to antiretroviral therapy and adherence to 
antidepressants while controlling for race/ethnicity, gender, antiretroviral 
regimen type, and total number of medications. 
 H013: Among patients taking antipsychotics, there will be no significant 
relationship between adherence to antiretroviral therapy and adherence to 
mood stabilizers while controlling for race/ethnicity, gender, antiretroviral 
regimen type, and total number of medications. 
 H014: Among patients taking mood stabilizers, there will be no significant 
relationship between adherence to antiretroviral therapy and adherence to 
antipsychotics while controlling for race/ethnicity, gender, antiretroviral 
regimen type, and total number of medications. 
 26
Rationale for H011 through H014: Previous studies indicate that adherence to 
psychotropic medications, specifically antidepressants, may be associated with 
adherence to antiretroviral therapy.31,33 
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This chapter describes the research methods used to test the hypotheses stated 
in Chapter One.  The design of the study is specified, along with the criteria for 
patient selection.  Definitions are provided for the primary outcome measures used 
and the statistical analyses used to test each study hypothesis are explained. 
 
STUDY DESIGN 
This is a retrospective cohort study using data extracted from the Texas 
Medicaid Vendor Drug Program database and Texas Medicaid enrollment files.  
Texas Medicaid, which is overseen by the Texas Health and Human Services 
Commission, provides medical coverage for eligible indigent patients in the state of 
Texas.  Coverage is provided for up to three outpatient prescriptions per month 
(limited to a 185-day supply), though some beneficiaries are exempt from the three 
prescriptions per month limitation.1,2 
Data were extracted over the period from January 1, 2003 to December 31, 
2005.  This timeframe was chosen to avoid the complicating factor of patients who 
were previously dually-eligible for Medicaid and Medicare being switched to a 
Medicare Part D prescription drug plan in November 2006.  Prescription claims data 
were used to identify the target study population (adult patients starting a new 
combination antiretroviral regimen during the year 2004), as well as the subgroup of 
patients receiving psychotropic medications.  Important covariates, including patient 
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gender and race/ethnicity, were extracted from the Texas Medicaid Vendor Drug 
Program database and Texas Medicaid enrollment files, respectively.  Claims data 
were also used to determine antiretroviral regimen type and total number of 
prescribed medications.  Adherence to and persistence with combination antiretroviral 
therapy, as well as adherence to psychotropic medications when applicable, were 
evaluated over the 12-month period following antiretroviral therapy initiation. 
 
STUDY POPULATION 
Subjects eligible for inclusion in this study were those 18-64 years of age with 
prescription claims for at least three antiretroviral medications indicated for treatment 
of HIV infection within a 3-month period between January 1, 2004 and December 31, 
2004 (Table 2.1).  Claims for at least three antiretroviral medications were required 
since all combination antiretroviral regimens recommended for treatment of HIV 
infection in 2004 consisted of at least three antiretroviral agents.3-5  A 3-month index 
period was chosen to allow patients who were limited to three prescriptions per 
month an opportunity to acquire the individual components of their combination 
antiretroviral regimens over multiple months.  This often becomes necessary when 
patients are being treated with other costly medications for comorbid conditions.  In 
order to target a population of patients starting a new combination antiretroviral 
regimen, patients were excluded if they had any claims for antiretroviral medications 
in the 3 months prior to the index period.  Included patients were required to have 
continuous enrollment in Medicaid for the 3 months prior to and 12 months following 
the index period.   
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Assuming a ratio of 1:2 for patients with mental disorders to those without, 
the sample size needed to detect a minimum relative risk of adherence to combination 
antiretroviral therapy of 0.75 with 80% power and α = 0.05 is 990.  This estimate is 
based on data from a previous study indicating that the rate of adherence to 














Table 2.1 Antiretroviral Medications for Treatment of HIV Infection Available in 
2004 
Generic Name Brand Name 
































Subgroup of Patients with Mental Disorders 
In this study, a mental disorder was defined as having a prescription claim for 
an antidepressant, mood stabilizer, and/or antipsychotic agent between January 1, 
2004 and December 31, 2004 (Tables 2.3-2.5).  To avoid including patients in this 
subgroup who were using psychotropic medications for insomnia rather than a mental 
disorder, minimum doses for inclusion were required for quetiapine (≥ 300 mg/day) 
and tricyclic antidepressants (≥ 75 mg/day).  A dose of 300 mg/day was chosen as the 
minimum for quetiapine since this is the lowest dose shown to be effective for 
treatment of bipolar disorder and schizophrenia.7  The minimum dose of 75 mg/day 
chosen for the tricyclic antidepressants is based on a Cochrane review which found 
that low dosages of tricylclic antidepressants, generally 75-100 mg/day, were 
effective for treatment of depression.8  Trazodone was excluded from the list of 
antidepressants used to denote presence of a mental disorder since this medication is 
more often used to treat insomnia than depression.  Prochlorperazine was excluded 
from the list of antipsychotic agents used to denote presence of a mental disorder 
since this medication is primarily used for treatment of nausea rather than psychosis.  
Claims for injectable antipsychotic agents were excluded due to inconsistencies in the 
days supply entered in the database and the fact that claims for these medications are 
not consistently processed through the Texas Medicaid Vendor Drug Program.  
Claims for the olanzapine/fluoxetine combination or the perphenazine/amitriptyline 
combination were included in analyses for both antipsychotics and antidepressants as 
appropriate. 
In order to separate anticonvulsant agents used for epilepsy from those used 
for mood stabilization, only anticonvulsants that have at least one formulation with a 
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current FDA-approved indication for treatment of bipolar disorder were considered to 
be mood stabilizers for this study.  These are valproic acid, divalproex sodium, 
carbamazepine, and lamotrigine.9-11  Patients receiving other anticonvulsants in 
addition to those considered to be mood stabilizers during the 12-month evaluation 
period were considered to be treated for a seizure disorder and excluded from the 
subgroup of patients with mental disorders.  Additionally, patients taking a mood-
stabilizing anticonvulsant were required to have a claim for at least one other 
psychotropic agent (i.e., antidepressant, lithium, and/or antipsychotic) during the 12-
month evaluation period to be included in the subgroup of patients with mental 
disorders (Tables 2.2-2.4).  This increases the likelihood that these anticonvulsants 















Table 2.2 Antidepressants Available in 2004 
Generic Name Brand Name 



































Table 2.3 Mood Stabilizers Available in 2004 
Generic Name Brand Name(s) 
Anticonvulsants 







Table 2.4 Antipsychotics Available in 2004 

























Adherence to combination antiretroviral therapy was assessed using 
prescription claims data.  The primary adherence measure was the Proportion of Days 
Covered (PDC) across all antiretroviral medications in the index regimen.12  This 
measure was chosen over the commonly used Medication Possession Ratio (MPR) 
because the PDC provides a more conservative estimate of medication adherence 
when multiple medications in the same class are used concomitantly.  While the 
numerator of the MPR is merely a sum of the number of days supplied for a 
medication, the numerator of the PDC is calculated using a set of rules that avoids 
double-counting days of medication coverage.  Therefore, values for the PDC range 
from 0 to 1.12  The PDC for combination antiretroviral therapy was calculated by 
determining the total number of days during the 12-month follow-up period for which 
all index antiretrovirals were available and dividing by 365 days.  Adherence to 
antiretroviral therapy was dichotomized based on calculated PDCs.  Patients with a 
PDC ≥ 90% were considered adherent to combination antiretroviral therapy for the 
primary analyses, though sensitivity analyses were also performed using PDC values 
of ≥ 95%, ≥ 85%, and ≥ 80% as the cutoffs for antiretroviral adherence.  Assessing 
multiple levels of antiretroviral adherence was considered to be valuable given the 
recent evidence indicating that many patients taking newer combination antiretroviral 
regimens will achieve desired clinical outcomes at adherence levels below 95%.13-15  
Patients with a PDC ≥ 80% for antidepressants, antipsychotics, and mood stabilizers 
were considered adherent to psychotropic medications, based on convention.  When 
more than one psychotropic medication was used during the evaluation period, the 
PDC for psychotropics was calculated as the mean adherence across drug classes. 
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Persistence was measured as the number of days that a patient was persistent 
with combination antiretroviral therapy.  A gap in treatment of greater than 60 days 
(days supply dispensed plus a 60 day grace period) constituted the end of the 
treatment period for each individual drug.  In a multicenter, National Institutes of 
Health-sponsored study of structured antiretroviral treatment interruption, the mean 
time to early termination of treatment interruption due to a decline in CD4 
lymphocyte count, an increase in HIV RNA levels, and/or disease progression was 
2.3 months.16   Therefore, a gap in treatment of 60 days is likely to result in clinically 
significant adverse outcomes.  The number of days persistent was calculated by 
summing the number of days from the first date on which all index medications were 
available to the last date before which no gaps in treatment with all index medications 
greater than 60 days occurred. 
 
STATISTICAL ANALYSES 
Statistical analyses for this study were performed using SPSS® Version 15.0 
for Windows.17  All tests were two-sided.  The threshold for statistical significance 
was defined as α = 0.05 for all tests.  Frequencies and percentages were used to 
describe the study population in terms of categorical baseline variables 
(race/ethnicity, gender, psychotropic medication use, types of antiretroviral regimens 
prescribed), while descriptive statistics were used to evaluate continuous baseline 
variables (age, total number of medications).  Assumptions for each statistical test 
were checked to evaluate validity, and tests were performed to rule out 
multicollinearity for variables entered into regression equations.  Table 2.5 provides a 
list of the statistical analyses used for hypothesis testing.   
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For objective one, Pearson chi-square analyses were used to evaluate 
differences in the proportion of patients using psychotropic medications among 
population subgroups based on race/ethnicity and gender.  For all analyses, 
race/ethnicity was categorized as black, white, Hispanic, or other, and gender was 
dichotomized as male and female. 
Objective two examines the relationship between mental disorders and 
antiretroviral adherence and persistence.  Logistic regression was used to evaluate the 
relationship between adherence based on PDC and psychotropic medication use, 
controlling for race/ethnicity, gender, antiretroviral regimen type, and total number of 
medications.  Controlling for these same factors, multiple linear regression was used 
to evaluate the relationship between psychotropic medication use and number of days 
persistent.  For all analyses, antiretroviral regimen type was classified as NNRTI-
based, ritonavir boosted PI-based, unboosted PI-based, triple NRTI, or other.  Total 
number of medications included antiretrovirals, psychotropics, and all other 
medications prescribed over the 3-month index period to serve as an indicator of 
overall pill burden. 
In addition to the regression analyses, factorial ANOVA was used to test for 
significant interactions between psychotropic medication use, race/ethnicity, and 
gender with regard to effects on PDC (treated as a continuous variable) and number 
of days persistent.  Factorial ANOVA allows for testing of the three way interaction 
between psychotropic medication use, race/ethnicity, and gender, which assessed 
whether particular subsets of the mentally ill population (e.g. Hispanic females, white 
males) were at greater risk for antiretroviral nonadherence. 
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For objective three, logistic regression was used to evaluate the relationship 
between adherence to antiretroviral therapy and adherence to psychotropic 
medications, controlling for race/ethnicity, gender, antiretroviral regimen type, and 
total number of medications.   Models for overall psychotropic medication adherence, 
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Abbreviations: Measmt = measurement; DV = dependent variable; IV = independent variable; ARV = 
antiretroviral; MPR = medication possession ratio; ANOVA = analysis of variance 
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This chapter describes the demographic characteristics of the study population 
and presents the results of the analyses described in Chapter Two.  Data for this study 
were collected from the Texas Medicaid Vendor Drug Program database and Texas 
Medicaid enrollment files. During 2004, 171,230 claims for antiretroviral medications 
were made to Texas Medicaid for 5,138 individual patients aged 18-64.  After 
applying inclusion and exclusion criteria for number of antiretroviral agents in the 
index regimen, claims for antiretrovirals in the previous three months, and continuous 
enrollment, a total of 1,321 patients using combination antiretroviral therapy were 
included in the sample (Table 3.1). 
 
Table 3.1 Summary of Subjects Meeting Inclusion Criteria 
Criterion Number 
Total number of subjects with an ARV claim during 
2004 
                    5,699 
Number of subjects ages 18-64
[-561] 
                   5,138 
Number of subjects with claims for at least 3 ARVs 
within 3 months starting in 2004 
[-955] 
                   4,183 
Number of subjects with no ARV claims in 3 months 
prior to index      
[-2,711] 
                    1,472 
Number of subjects with continuous enrollment in 
Texas Medicaid 
[-151] 
                    1,321   
Total number of subjects meeting inclusion criteria                     1,321 




Demographic characteristics for the 1,321 patients included in the sample are 
displayed in Table 3.2.  The mean age of all subjects was 40.2 ± 9.3 years, with a 
range of 18 to 64 years.  Males and females were almost equally represented, with 
males accounting for 52.4% of the sample.  The most common racial/ethnic group 
was black (53.1%), followed by white (22.7%) and Hispanic (13.9%).  Most patients 
in the sample were using a nonnucleoside reverse transcriptase inhibitor (NNRTI)-
based regimen at baseline (31.5%), though ritonavir-boosted protease inhibitor (PI)-
based regimens (28.6%) and unboosted PI-based regimens (21.6%) were also 
commonly used.  The mean number of antiretroviral drugs in the initial regimen 
across the entire sample was 3.4 ± 0.8, with a range from three to eight.  The total 
number of medications being used over the 3-month index period ranged from one to 
thirty, with a mean of 7.3 ± 4.6.  The reason that some patients in the sample had a 
total number of medications less than three is because the total number of 
medications used, which represents total pill burden, does not take into account that 
some dosage forms represent combination medications.  All patients listed as having 








Table 3.2 Baseline Demographic Characteristics of Patients Using Combination 
Antiretroviral Therapy 
Characteristic All Included Subjects (N = 1,321)
Age, mean ± SD (yrs)                       40.2 ± 9.3 
Male, number (%)                       692 (52.4%) 
Race/Ethnicity, number (%) 
     Black 
     White 
     Hispanic 
     Other 
                       702 (53.1%) 
                       300 (22.7%) 
                       183 (13.9%) 
                       136 (10.3%) 
ARV regimen type, number (%)
     NNRTI-based 
     Ritonavir boosted PI-based  
     Unboosted PI-based 
     Triple NRTI 
     Other 
                       416 (31.5%) 
                       378 (28.6%) 
                       285 (21.6%) 
                       121 (9.2%) 
                       121 (9.2%) 
Number of ARV drugs in 
     index regimen, mean ± SD 
                       3.4 ± 0.8 
Total number of medications, mean ± SD                       7.3 ± 4.6 
Abbreviations: SD = standard deviation, ARV = antiretroviral, NNRTI = nonnucleoside 




Of the 1,321 patients included in the sample, 501 (37.9%) met the study 
criteria for having a mental disorder based on psychotropic drug use.  Table 3.3 
displays the demographic characteristics of the sample by psychotropic medication 
use.  The mean age for patients using psychotropic medications (41.7 years, SD = 7.8) 
was significantly greater than the mean age for those not using psychotropics (39.3 
years, SD = 10.0, p < 0.001), with a mean difference of 2.4 years.  No significant 
differences were observed between subjects using psychotropics and those who were 
not with regard to type of antiretroviral regimen used or the number of antiretroviral 
drugs in the index regimen. Patients using psychotropic medications had a 
significantly higher mean total number of medications at baseline (8.9, SD = 5.4) 
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compared to those who did not use psychotropics (6.3, SD = 3.7, p < 0.001).  
Differences among groups based on race/ethnicity and gender are outlined in the 
results of objective one. 
 
Table 3.3 Baseline Demographic Characteristics of Patients Using Combination 








(n = 820) Statistic ρ-value
Age, mean ± SD (yrs)    41.7 ± 7.8   39.3 ± 10.0 t (1246.3) = 4.94  <0.001
Male, number (%)   261 (52.1%)   431 (52.6%)   χ2 (1) = 0.03    0.87
Race/Ethnicity, number (%) 
     Black 
     White 
     Hispanic 
     Other 
   231 (46.1%) 
   148 (29.5%) 
     69 (13.8%) 
     53 (10.6%) 
   471 (57.4%) 
   152 (18.5%) 
   114 (13.9%) 
     83 (10.1%) 
  χ2 (3) = 24.16  <0.001
ARV regimen type, number (%) 
     NNRTI-based 
     Ritonavir boosted PI-based 
     Unboosted PI-based      
     Triple NRTI 
     Other 
   162 (32.3%) 
   133 (26.5%) 
   103 (20.6%) 
     46 (9.2%) 
     57 (11.4%) 
   254 (31.0%) 
   245 (29.9%) 
   182 (22.2%) 
     75 (9.1%) 
     64 (7.8%) 
  χ2 (4) = 6.11    0.19
Number of ARV drugs in 
     index regimen, mean ± SD      3.4 ± 0.9      3.4 ± 0.8  t (962.8) = 1.64 
 
   0.10 
Total number of medications, 
     mean ± SD      8.9 ± 5.4      6.3 ± 3.7  t (780.3) = 9.76 
 
 <0.001 
Abbreviations: SD = standard deviation, ARV = antiretroviral, NNRTI = nonnucleoside reverse 






OBJECTIVE ONE: EXAMINATION OF THE RELATIONSHIP BETWEEN 
PSYCHOTROPIC MEDICATION USE AND RACE/ETHNICITY AND GENDER AMONG 
PATIENTS WITH HIV 
This objective examines whether women and/or racial/ethnic minorities being 
treated for HIV are more likely to have concomitant treatment for mental disorders.  
Pearson chi-square tests were used to evaluate differences in the proportion of 
subjects using psychotropic medications based on race/ethnicity and gender.  As 
shown in Table 3.3, no significant relationship was found between subjects’ gender 
and psychotropic medication use (χ2 = 0.03, df = 1, p = 0.87).  However, a chi-square 
analysis did reveal a significant relationship between race/ethnicity and use of 
psychotropic medications (χ2 = 24.16, df = 3, p < 0.001). Among white patients, the 
proportion of patients using psychotropic medications (49.3%) was approximately 
equal to the proportion of those who were not (50.7%).  For patients who were black, 
Hispanic, or whose race/ethnicity was classified as “other,” the proportion of patients 
using psychotropic medications (32.9%, 37.7%, and 39.0%, respectively) was 
markedly lower than the proportion of patients who were not using psychotropics 
(67.1%, 62.3%, and 61.0%, respectively).  (Note: Table 3.3 shows column 
percentages, whereas above data represent row percentages). 
 
Results of Hypothesis Testing 
Objective One:  To compare the prevalence of psychotropic medication use among 




H01: There will be no significant difference in the prevalence of psychotropic 
medication use among HIV-infected patients based on race/ethnicity. 
Result: Hypothesis is rejected. The proportion of patients using psychotropic 
medications varied based on race/ethnicity, with blacks, Hispanics, and patients with 
a race classified as “other” having a lower proportion of psychotropic medication 
use (32.9%, 37.7%, and 39.0%, respectively) than whites (49.3%). 
 
H02: There will be no significant difference in the prevalence of psychotropic 
medication use among HIV-infected patients based on gender. 
Result: Hypothesis not rejected. No significant relationship was observed between 
gender and psychotropic medication use among patients treated for HIV infection. 
 
OBJECTIVE TWO: EXAMINING THE RELATIONSHIP BETWEEN PSYCHOTROPIC 
MEDICATION USE AND ANTIRETROVIRAL ADHERENCE AND PERSISTENCE 
This objective was designed to study whether psychotropic medication use is 
related to adherence to and persistence with combination antiretroviral therapy.  
Antiretroviral adherence and persistence were calculated for each subject as described 
in Chapter 2.  The mean adherence to combination antiretroviral therapy, as measured 
by proportion of days covered (PDC), across the entire sample was 39.1% ± 34.6%.  
The mean persistence with antiretroviral therapy in this sample was 140.3 ± 137.6 
days.  T-test results revealed no significant differences between subjects using 
psychotropic medications and those who were not in mean PDC (t = 0.30, df = 1319, 
p = 0.76) or mean number of days persistent (t = 0.30, df = 1319, p = 0.77; Table 3.4).  
Because of the large standard deviations for mean PDC and mean number of days 
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persistent, nonparametric tests were also conducted.  A Mann-Whitney U test showed 
no significant difference in mean PDC between patients using psychotropic 
medications (median = 25.5%, mean = 39.5%, SD = 33.7%) and those who were not 
(median = 24.9%, mean = 38.9%, SD = 35.2%) (Z = -0.31, p = 0.76). A 
nonsignificant difference was also found from a Mann-Whitney U test evaluating 
mean number of days persistent between users (median = 88.0, mean = 141.7, SD = 
135.8) and nonusers (median = 68.0, mean = 139.4, SD = 138.8) of psychotropic 
medications (Z = -0.62, p = 0.53). 
 
Table 3.4 T-test Comparison of Unadjusted Mean Proportion of Days Covered and 
Mean Number of Days Persistent by Use of Psychotropic Medications 








(n = 820) Statistic ρ-value
Mean PDC (%)     39.5 ± 33.7  38.9 ± 35.2 t (1319) = 0.30    0.76
Mean # Days Persistent   141.7 ± 135.8 139.4 ± 138.8 t (1319) = 0.30    0.77
Abbreviations: PDC = proportion of days covered
 
Adherence 
Binary logistic regression models controlling for race/ethnicity, gender, 
antiretroviral regimen type, and total number of medications were used to examine 
the relationship between PDC and use of psychotropic medications.  Adherence to 
antiretroviral therapy was dichotomized based on PDC value, where subjects having a 
PDC ≥ 90% were considered to be adherent for the primary analysis.  Similar 
regressions were conducted for adherence defined as PDC ≥ 95%, PDC ≥ 85% , and 
PDC ≥ 80% to evaluate the sensitivity of the model.  After controlling for potential 
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confounders, the odds of having at least 90% adherence to combination antiretroviral 
therapy as measured by PDC was not significantly associated with using psychotropic 
medications (OR = 0.90, p = 0.52, 95% CI: 0.65 – 1.24; Table 3.5).  As shown in 
Tables 3.6-3.8, the relationship between psychotropic medication use and adherence 
to combination antiretroviral therapy was nonsignificant for all other evaluated levels 
of adherence (i.e. 95%, 85%, and 80%).   
 
Table 3.5 Results from Binary Logistic Regression Models Analyzing the 
Relationship between Psychotropic Medication Use and At Least 90% 






Error Wald χ2 p-value 
Odds 




          -0.11       0.17    0.42    0.52    0.90 
 
    0.65 – 1.24 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
          -0.13 
           0.03 
          -0.25 
      0.19 
      0.25 
      0.30 
   0.44 
   0.02 
   0.69 
   0.51 
   0.90 
   0.41 
   0.88 
   1.03 
   0.78 
 
    0.61 – 1.28 
    0.63 – 1.68 
    0.43 – 1.41 
Genderd            0.10      0.16   0.46   0.51   1.11     0.82 – 1.50
ARV regimen 
typee 
   Boosted PI 
   Unboosted PI    
   Triple NRTI 
   Other 
 
 
          -0.62 
          -0.41 
          -0.40 
          -0.77 
 
      0.20 
      0.20 
      0.27 
      0.33 
 
   9.90 
   4.01 
   2.14 
   5.37 
 
   0.002 
   0.05 
   0.14 
   0.02 
 
   0.54 
   0.67 
   0.67 
   0.47 
 
 
    0.36 – 0.79 
    0.45 – 0.99 
    0.39 – 1.15 
    0.24 – 0.89 
Total # of 
medications 
 
          -0.07       0.02    9.51    0.002    0.93 
 
    0.90 – 0.98 
Abbreviations: CI = confidence interval, ARV = antiretroviral, PI = protease inhibitor,  
NRTI = nucleoside reverse transcriptase inhibitor 
a Adherence defined as proportion of days covered (PDC) 
Model Chi-Square = 33.73, df = 11, p < 0.001 
Reference categories: b nonuse of psychotropics, c white, d male, e nonnucleoside reverse transcriptase  






Table 3.6 Results from Binary Logistic Regression Models Analyzing the 
Relationship between Psychotropic Medication Use and At Least 95% 






Error Wald χ2 p-value 
Odds 




          -0.06       0.19    0.09    0.77    0.95 
 
    0.66 – 1.37 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
          -0.19 
           0.16 
          -0.05 
      0.22 
      0.27 
      0.32 
   0.74 
   0.35 
   0.02 
   0.39 
   0.56 
   0.89 
   0.83 
   1.17 
   0.96 
 
    0.54 – 1.27 
    0.69 – 2.00 
    0.51 – 1.80 
Genderd            0.06      0.18   0.11   0.74   1.06     0.75 – 1.49
ARV regimen 
typee 
   Boosted PI 
   Unboosted PI    
   Triple NRTI 
   Other 
 
 
          -0.57 
          -0.44 
          -0.80 
          -1.05 
 
      0.22 
      0.23 
      0.34 
      0.41 
 
   6.78 
   3.73 
   5.40 
   6.37 
 
   0.01 
   0.05 
   0.02 
   0.01 
 
   0.57 
   0.65 
   0.45 
   0.35 
 
 
    0.37 – 0.87 
    0.42 – 1.01 
    0.23 – 0.88 
    0.16 – 0.79 
Total # of 
medications 
 
          -0.08       0.03    9.77    0.002    0.92 
 
    0.88 – 0.97 
Abbreviations: CI = confidence interval, ARV = antiretroviral, PI = protease inhibitor,  
NRTI = nucleoside reverse transcriptase inhibitor 
a Adherence defined as proportion of days covered (PDC) 
Model Chi-Square = 34.41, df = 11, p < 0.001 
Reference categories: b nonuse of psychotropics, c white, d male, e nonnucleoside reverse transcriptase  














Table 3.7 Results from Binary Logistic Regression Models Analyzing the 
Relationship between Psychotropic Medication Use and At Least 85% 






Error Wald χ2 p-value 
Odds 




          -0.09       0.16    0.34    0.56    0.91 
 
    0.67 – 1.24 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
          -0.21 
          -0.19 
          -0.24 
      0.18 
      0.24 
      0.27 
   1.38 
   0.64 
   0.78 
   0.24 
   0.42 
   0.38 
   0.81 
   0.83 
   0.79 
 
    0.57 – 1.15 
    0.52 – 1.32 
    0.46 – 1.34 
Genderd           -0.01      0.15   0.01   0.93   0.99     0.74 – 1.31
ARV regimen 
typee 
   Boosted PI 
   Unboosted PI    
   Triple NRTI 
   Other 
 
 
          -0.59 
          -0.32 
          -0.30 
          -0.87 
 
      0.19 
      0.19 
      0.25 
      0.32 
 
 10.01 
   2.80 
   1.37 
   7.44 
 
   0.002 
   0.10 
   0.24 
   0.01 
 
   0.56 
   0.73 
   0.74 
   0.42 
 
 
    0.39 – 0.80 
    0.50 – 1.06 
    0.45 – 1.22 
    0.23 – 0.78 
Total # of 
medications 
 
          -0.07       0.02  11.37    0.001    0.93 
 
    0.90 – 0.97 
Abbreviations: CI = confidence interval, ARV = antiretroviral, PI = protease inhibitor,  
NRTI = nucleoside reverse transcriptase inhibitor 
a Adherence defined as proportion of days covered (PDC) 
Model Chi-Square = 38.32, df = 11, p < 0.001 
Reference categories: b nonuse of psychotropics, c white, d male, e nonnucleoside reverse transcriptase  













Table 3.8 Results from Binary Logistic Regression Models Analyzing the 
Relationship between Psychotropic Medication Use and At Least 80% 






Error Wald χ2 p-value 
Odds 




          -0.08       0.15    0.27    0.61    0.93 
 
    0.69 – 1.24 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
          -0.29 
          -0.09 
          -0.37 
      0.17 
      0.22 
      0.27 
   2.81 
   0.18 
   1.90 
   0.09 
   0.68 
   0.17 
   0.75 
   0.91 
   0.69 
 
    0.54 – 1.05 
    0.59 – 1.41 
    0.41 – 1.17 
Genderd            0.03      0.14   0.03   0.86   1.03     0.78 – 1.35
ARV regimen 
typee 
   Boosted PI 
   Unboosted PI    
   Triple NRTI 
   Other 
 
 
          -0.54 
          -0.29 
          -0.37 
          -0.84 
 
      0.18 
      0.18 
      0.25 
      0.30 
 
   9.35 
   2.54 
   2.22 
   7.76 
 
   0.002 
   0.11 
   0.14 
   0.01 
 
   0.58 
   0.75 
   0.69 
   0.43 
 
 
    0.41 – 0.82 
    0.52 – 1.07 
    0.42 – 1.12 
0.24 – 0.78 
Total # of 
medications 
 
          -0.06       0.02    9.96    0.002    0.94 
 
    0.91 – 0.98 
Abbreviations: CI = confidence interval, ARV = antiretroviral, PI = protease inhibitor,  
NRTI = nucleoside reverse transcriptase inhibitor 
a Adherence defined as proportion of days covered (PDC) 
Model Chi-Square = 37.43, df = 11, p < 0.001 
Reference categories: b nonuse of psychotropics, c white, d male, e nonnucleoside reverse transcriptase  
     inhibitor (NNRTI) 
 
In an effort to determine whether particular subsets of the mentally ill 
population are at greater risk for antiretroviral nonadherence, factorial analysis of 
variance (ANOVA) was conducted to evaluate the interactions between psychotropic 
medication use, race/ethnicity, and gender with regard to effects on PDC.  Table 3.9 
displays the results for the factorial ANOVA with PDC as the dependent variable.  
The overall F-test for the model was significant (F = 1.66, df = 15, p = 0.05).  
Because the ANOVA showed a significant interaction between psychotropic 
medication use and race/ethnicity (F = 2.59, df = 3, p = 0.05), the main effects are not 
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interpreted. The interaction revealed that the relationship between psychotropic 
medication use and adherence to antiretroviral therapy measured by PDC varied by 
race/ethnicity.  The mean PDC was similar for those who were and were not using 
psychotropics among whites (42.9% ± 34.5% vs. 42.7% ± 36.1%), blacks (35.5% ± 
32.8% vs. 38.0% ± 34.7%), and Hispanics (42.3% ± 33.4% vs. 44.9% ± 36.7%).  
However, for patients with a race/ethnicity classified as “other,” mean PDC was 
higher for patients using psychotropic medications (43.4% ± 34.8%) than for those 
who were not (28.4% ± 32.0%).  While Levene’s test for homogeneity of variance 
was not significant (p = 0.057), it does indicate a trend toward heterogeneity in the 
population variances.  Since group sizes were markedly different, differences in the 
population variances can lead to unstable estimates of significance and increase the 
risk of a type-1 error.  The testing of multiple hypotheses inherent in a three way 
factorial ANOVA design also increases the risk of a false positive result.  Therefore, 

















Table 3.9 Results from a Factorial Analysis of Variance Analyzing the Interactions 
between Psychotropic Medication Use, Race/Ethnicity, and Gender in 
their Effects on Adherence to Combination Antiretroviral Therapy       
(N = 1321)a 




Square F p-value 
Observed 
Powerb 
Use of Psychotropics        1    0.23    0.23    1.95     0.16       0.29
Race/Ethnicity        3   1.26     0.42    3.52     0.02       0.78
Gender        1   0.15    0.15  1.24     0.27       0.20
Use of Psychotropics* 
Race/Ethnicity 
 
       3       0.92       0.31       2.59       0.05 
 
      0.64 
Use of Psychotropics* 
Gender 
 
       1       0.03       0.03       0.24       0.62 
 
      0.08 
Use of Psychotropics* 
Race/Ethnicity*Gender 
 
       6       0.67       0.11       0.94       0.47 
 
      0.38 
Error  1305  155.48    0.12        —        —         —
Abbreviations: df = degrees of freedom
a Adherence defined as proportion of days covered (PDC) 
b Computed using α = 0.05 
Model F-test = 1.66, df = 15, p = 0.05 
 
Table 3.10 Mean Proportion of Days Covered by Population Subgroups Based on Use 
of Psychotropic Medications and Race/Ethnicity (N = 1321)a 
 
Race/Ethnicity 
Subjects Using Psychotropics         
(n = 501) 
Subjects Not Using Psychotropics     
(n = 820) 
Black 35.5 ± 32.8 38.0 ± 34.7 
White 42.9 ± 34.5 42.7 ± 36.1 
Hispanic 42.3 ± 33.4 44.9 ± 36.7 
Other 43.4 ± 34.8 28.4 ± 32.0 







The relationship between psychotropic medication use and number of days 
persistent was evaluated using a multiple linear regression model, which controlled 
for race/ethnicity, gender, antiretroviral regimen type, and total number of 
medications.  Results of this regression are presented in Table 3.11.  The overall 
multiple regression model was significant (adjusted R2 = 0.03, F [10,1310] = 4.46,     
p < 0.001), with the included variables accounting for 2.5% of the variance in number 
of days persistent.  Psychotropic medication use was not found to be significantly 
















Table 3.11 Results from a Multiple Linear Regression Model Analyzing the 
Relationship between Psychotropic Medication Use and Persistence with 





Coefficients   
Persistence B 
Standard 
Error β T p-value 




       4.99 
     
       8.13 
   
          0.02 
 
          0.61 
     
          0.54 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
    -22.37 
      -0.30 
    -29.77 
 
       9.60 
     12.84 
     14.15 
         -0.08 
         -0.001 
         -0.07 
         -2.33 
         -0.02 
         -2.10 
 
          0.02 
          0.98 
          0.04 
Genderd       0.54        7.70          0.002          0.07           0.95
ARV regimen 
typee 
   Boosted PI 
   Unboosted PI 
   Triple NRTI 
   Other 
 
 
    -39.94 
    -19.83 
    -15.12 
    -54.71 
 
 
       9.76 
     10.49 
     14.04 
     14.28 
 
         -0.13 
         -0.06 
         -0.03 
         -0.12 
 
         -4.09 
         -1.89 
         -1.08 
         -3.83 
 
 
      < 0.001 
         0.06 
         0.28 
      < 0.001 
Total # of 
medications 
 
      -1.78 
 
       0.87          -0.06          -2.05 
 
          0.04 
Abbreviations: ARV = antiretroviral, PI = protease inhibitor, NRTI = nucleoside reverse transcriptase 
inhibitor 
a Persistence defined as number of days on which all index antiretroviral medications were available 
Model F (10, 1310) = 4.46, p < 0.001 
Reference categories: b nonuse of psychotropics, c white, d male, e nonnucleoside reverse transcriptase  
     inhibitor (NNRTI) 
 
Factorial ANOVA was used to test the interactions between psychotropic 
medication use, race/ethnicity, and gender with regard to effects on number of days 
persistent.  The results of this analysis are displayed in Table 3.12.  Because the 
overall F-test for the model was nonsignificant (F = 1.37, df = 15, p = 0.16), 
interaction effects were not interpreted.  As discussed with the previous ANOVA 
model, heterogeneity of variance (Levene’s test significant with p = 0.004) combined 
with unequal group sizes confers instability to estimates of main and interaction 
effects. 
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Table 3.12 Results from a Factorial Analysis of Variance Analyzing the Interactions 
between Psychotropic Medication Use, Race/Ethnicity, and Gender in 
their Effects on Persistence with Combination Antiretroviral Therapy  
(N = 1321)a 




Square F p-value 
Observed 
Powerb 
Use of Psychotropics        1      24579.54 24579.54    1.30      0.25       0.21
Race/Ethnicity        3    181325.48 60441.83   3.20      0.02       0.74
Gender        1        5409.42   5409.42    0.29      0.59       0.08
Use of Psychotropics* 
Race/Ethnicity 
 
       3      126397.63  42132.55     2.23       0.08 
 
      0.57 
Use of Psychotropics* 
Gender 
 
       1              20.84        20.84     0.001       0.97 
 
      0.05 
Use of Psychotropics* 
Race/Ethnicity*Gender 
 
       6        44453.18    7408.86     0.60       0.88 
 
      0.17 
Error  1305 24616287.30 18863.06      —       —       —
Abbreviations: df = degrees of freedom
a Persistence defined as number of days on which all index antiretroviral medications were available 
b Computed using α = 0.05 
Model F-test = 1.37, df = 15, p = 0.16 
 
Results of Hypothesis Testing 
Objective Two: To examine the relationship between psychotropic medication use 
and antiretroviral adherence and persistence, taking into account race/ethnicity and 
gender. 
 
H03: There will be no significant difference in the rate of adherence to antiretroviral 
therapy between those with and those without psychotropic medication use after 
controlling for race/ethnicity, gender, antiretroviral regimen type, and total number of 
medications. 
Result: Hypothesis not rejected. The odds of being noncompliant with combination 
antiretroviral therapy were not related to use of psychotropic medications. 
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H04: There will be no significant difference in the rate of adherence to antiretroviral 
therapy based on the interaction between psychotropic medication use and 
race/ethnicity. 
Result: Hypothesis is rejected.  While the mean PDC was similar for those who were 
and were not using psychotropics among whites (42.9% ± 34.5% vs. 42.7% ± 36.1%), 
blacks (35.5% ± 32.8% vs. 38.0% ± 34.7%), and Hispanics (42.3% ± 33.4% vs. 
44.9% ± 36.7%), the mean PDC was higher for patients using psychotropic 
medications (43.4% ± 34.8%) than for those who were not (28.4% ± 32.0%) among 
patients with a race/ethnicity classified as “other.”   
 
H05: There will be no significant difference in the rate of adherence to antiretroviral 
therapy based on the interaction between psychotropic medication use and gender. 
Result: Hypothesis not rejected.  No significant interaction was observed between 
psychotropic medication use and gender with regard to effects on antiretroviral 
adherence. 
 
H06: There will be no significant difference in the rate of adherence to antiretroviral 
therapy based on the interaction between psychotropic medication use, race/ethnicity, 
and gender. 
Result: Hypothesis not rejected.  No significant interaction was observed between 




H07: There will be no significant difference in persistence with antiretroviral therapy 
between those with and those without psychotropic medication use after controlling 
for race/ethnicity, gender, antiretroviral regimen type, and total number of 
medications. 
Result: Hypothesis not rejected. No significant relationship was observed between 
antiretroviral persistence and psychotropic medication use. 
 
H08: There will be no significant difference in persistence with antiretroviral therapy 
based on the interaction between psychotropic medication use and race/ethnicity. 
Result: Hypothesis not rejected.  No significant interaction was observed between 
psychotropic medication use and race/ethnicity with regard to effects on persistence 
with antiretroviral therapy. 
 
H09: There will be no significant difference in persistence with antiretroviral therapy 
based on the interaction between psychotropic medication use and gender. 
Result: Hypothesis not rejected.  No significant interaction was observed between 
psychotropic medication use and gender with regard to effects on persistence with 
antiretroviral therapy. 
 
H010: There will be no significant difference in persistence with antiretroviral therapy 
based on the interaction between psychotropic medication use, race/ethnicity, and 
gender. 
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Result: Hypothesis not rejected.  No significant interaction was observed between 
psychotropic medication use, race/ethnicity, and gender with regard to effects on 
persistence with antiretroviral therapy. 
 
OBJECTIVE THREE: EXAMINATION OF THE RELATIONSHIP BETWEEN 
ANTIRETROVIRAL ADHERENCE AND ADHERENCE TO PSYCHOTROPIC 
MEDICATIONS 
This objective was designed to examine whether a relationship exists between 
adherence to combination antiretroviral therapy and adherence to psychotropic 
medications.  Adherence to each class of psychotropic medication (antidepressants, 
mood stabilizers, and antipsychotics) was determined by calculating the number of 
days on which at least one medication in that class was available for use by the 
patient (proportion of days covered, PDC).  The mean PDC was 38.3% ± 34.2% for 
antidepressants (N = 443), 36.5% ± 33.5% for antipsychotics (N = 187), and 40.7% ± 
33.9% for mood stabilizers (N = 56).  The mean PDC across medication classes for 
patients using psychotropic medications was 36.7% ± 32.0% (N = 501), indicating a 
low level of adherence to psychotropics overall.  Table 3.13 displays the number and 
percent of patients who were at least 80% adherent to psychotropic medications in 











Patients achieving ≥ 80% adherence, 
Number (%) 
Antidepressants (N = 443)  86 (19.4%) 
Antipsychotics (N = 187) 33 (17.6%) 
Mood Stabilizers (N = 56) 12 (21.4%) 
All Psychotropics (N = 501) 81 (16.2%) 
a Percentages calculated as the number of patients achieving at least 80% adherence to the medication 
class divided by the total number of patients meeting study criteria for a mental disorder based on use 
of a drug from that class 
 
Binary logistic regression was used to test the relationship between PDC for 
antiretroviral therapy and PDC for psychotropics while controlling for race/ethnicity, 
gender, antiretroviral regimen type, and total number of medications.  This 
relationship was tested for adherence to psychotropics overall, as well as adherence to 
the individual drug classes.  Results from the binary logistic regression models testing 
the relationship between psychotropic medication adherence and at least 90% 
adherence to antiretroviral therapy are presented in Tables 3.14-3.17.  Patients who 
had a mean adherence of at least 80% to psychotropic medications overall were 3.37 
times more likely to be at least 90% adherent to combination antiretroviral therapy   
(p < 0.001, 95% CI: 1.86 – 6.10).   
When adherence to individual psychotropic medication classes was 
considered separately, the odds of having at least 90% adherence to antiretroviral 
therapy was significantly higher when patients were at least 80% adherent to 
antidepressants (OR = 4.23, p < 0.001, 95% CI: 2.31 – 7.75).  In sensitivity analyses, 
the relationship between adherence to psychotropic medications and adherence to 
combination antiretroviral therapy and the relationship between adherence to 
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antidepressants and adherence to combination antiretroviral therapy remained 
significant for all levels of antiretroviral adherence tested (95%, 85%, and 80%).   
Binary logistic regression models testing the relationship between adherence 
to antipsychotics and adherence to antiretroviral therapy were all found to be 
nonsignificant overall.   However, the odds ratio for antipsychotic adherence was 
found to be significant in the model for 90% (OR = 3.33, p = 0.02, 95% CI: 1.21 – 
9.19) adherence to antiretrovirals.  This suggests that a significant relationship 
between antipsychotic and antiretroviral adherence may exist, but that the sample was 
not adequately powered to evaluate this relationship.   
Due to the small number of patients using mood stabilizers who were also 
using a triple NRTI-based antiretroviral regimen, triple NRTI-based regimens were 
included in the category “other” for logistic regression analyses evaluating the 
relationship between adherence to mood stabilizers and adherence to antiretroviral 
therapy.  For binary logistic regression models testing the relationship between 
adherence to mood stabilizers and adherence to antiretroviral therapy, only the model 
evaluating predictors for at least 85% adherence to antiretrovirals was found to be 
significant (χ2 = 19.27; df = 9; p = 0.02), with adherence to mood stabilizers 
significantly associated with at least 85% adherence to antiretroviral therapy (OR = 
18.60, p = 0.04, 95% CI: 1.10 – 315.41).  As the other models evaluating this 
relationship were found to be nonsignificant, the significant relationship found with at 
least 85% adherence to antiretrovirals and adherence to mood stabilizers may have 
been a consequence of small cell sizes that can lead to unstable errors. 
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Table 3.14 Results from Binary Logistic Regression Models Analyzing the 
Relationship between At Least 80% Adherence to All Psychotropic 
Medications and At Least 90% Adherence to Combination Antiretroviral 






Error Wald χ2 p-value 
Odds 
Ratio 95% CI 
≥ 80% adherence to 
psychotropicsb 
 
            1.21       0.30   16.03  <0.001   3.37 
 
  1.86 – 6.10 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
           -0.10 
           -0.13 
            0.30 
      0.31 
      0.44 
      0.45 
    0.10   
    0.08 
    0.43 
   0.75 
   0.77 
   0.51 
  0.91 
  0.88 
  1.35 
 
  0.50 – 1.67 
  0.37 – 2.09 
  0.55 – 3.28 
Genderd             0.35      0.27    1.63   0.20  1.41   0.83 – 2.41
ARV regimen typee 
   Boosted PI 
   Unboosted PI     
   Triple NRTI 
   Other 
 
           -0.19 
           -0.07 
           -0.06 
           -0.82 
      0.35 
      0.36 
      0.46 
      0.58 
    0.30 
    0.04 
    0.02 
    2.06 
   0.58 
   0.84 
   0.90 
   0.15 
  0.83 
  0.93 
  0.94 
  0.44 
 
  0.42 – 1.64 
  0.46 – 1.86 
  0.39 – 2.30 
  0.14 – 1.35 
Total # of 
medications 
 
           -0.05       0.03     3.19    0.07   0.95 
 
  0.90 – 1.01 
Abbreviations: CI = confidence interval, ARV = antiretroviral, PI = protease inhibitor,  
NRTI = nucleoside reverse transcriptase inhibitor 
a Adherence defined as proportion of days covered (PDC) 
Model Chi-Square = 22.96, df = 10, p = 0.01 
Reference categories: b < 80% adherence to psychotropics, c white, d male, e nonnucleoside reverse  










Table 3.15 Results from Binary Logistic Regression Models Analyzing the 
Relationship between At Least 80% Adherence to Antidepressants and 
At Least 90% Adherence to Combination Antiretroviral Therapy          






Error Wald χ2 p-value 
Odds 
Ratio 95% CI 
≥ 80% adherence to 
antidepressantsb 
 
            1.44       0.31    21.80  <0.001   4.23 
 
  2.31 – 7.75 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
            0.001 
           -0.06 
            0.25 
      0.33 
      0.47 
      0.48 
    0.00   
    0.02 
    0.26 
   1.00 
   0.90 
   0.61 
  1.00 
  0.95 
  1.28 
 
  0.53 – 1.90 
  0.38 – 2.37 
  0.50 – 3.29 
Genderd             0.30      0.29    1.12   0.29  1.36   0.77 – 2.38
ARV regimen typee 
   Boosted PI 
   Unboosted PI     
   Triple NRTI 
   Other 
 
           -0.05 
           -0.002 
           -0.08 
           -1.06 
      0.37 
      0.38 
      0.47 
      0.66 
    0.02 
    0.00 
    0.03 
    2.60 
   0.89 
   1.00 
   0.87 
   0.11 
  0.95 
  1.00 
  0.93 
  0.35 
 
  0.47 – 1.95 
  0.48 – 2.08 
  0.37 – 2.31 
  0.10 – 1.26 
Total # of 
medications 
 
           -0.06       0.03     3.33    0.07   0.95 
 
  0.89 – 1.00 
Abbreviations: CI = confidence interval, ARV = antiretroviral, PI = protease inhibitor,  
NRTI = nucleoside reverse transcriptase inhibitor 
a Adherence defined as proportion of days covered (PDC) 
Model Chi-Square = 29.21, df = 10, p = 0.001 
Reference categories: b < 80% adherence to antidepressants, c white, d male, e nonnucleoside reverse  












Table 3.16 Results from Binary Logistic Regression Models Analyzing the 
Relationship between At Least 80% Adherence to Antipsychotics and At 






Error Wald χ2 p-value 
Odds 
Ratio 95% CI 
≥ 80% adherence to 
antipsychoticsb 
 
            1.20       0.52     5.40    0.02   3.33 
 
  1.21 – 9.19 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
           -0.29 
           -0.25 
            0.39 
      0.56 
      0.81 
      0.75 
    0.27   
    0.10 
    0.27 
   0.60 
   0.76 
   0.61 
  0.75 
  0.78 
  1.47 
 
  0.25 – 2.25 
  0.16 – 3.78 
  0.34 – 6.34 
Genderd             0.26      0.48    0.31   0.58  1.30   0.51– 3.32
ARV regimen typee 
   Boosted PI 
   Unboosted PI     
   Triple NRTI 
   Other 
 
           -0.03 
           -0.31 
            0.14 
           -0.14 
      0.59 
      0.74 
      0.76 
      0.76 
    0.002 
    0.18 
    0.03 
    0.04 
   0.96 
   0.67 
   0.86 
   0.85 
  0.97 
  0.73 
  1.15 
  0.87 
 
  0.31 – 3.06 
  0.17 – 3.10 
  0.26 – 5.11 
  0.20 – 3.82 
Total # of 
medications 
 
           -0.06       0.05     1.90    0.17   0.94 
 
  0.86 – 1.03 
Abbreviations: CI = confidence interval, ARV = antiretroviral, PI = protease inhibitor,  
NRTI = nucleoside reverse transcriptase inhibitor 
a Adherence defined as proportion of days covered (PDC) 
Model Chi-Square = 7.91, df = 10, p = 0.64 
Reference categories: b < 80% adherence to antipsychotics, c white, d male, e nonnucleoside reverse  












Table 3.17 Results from Binary Logistic Regression Models Analyzing the 
Relationship between At Least 80% Adherence to Mood Stabilizers and 
At Least 90% Adherence to Combination Antiretroviral Therapy          










Ratio 95% CI 
≥ 80% adherence to 
mood stabilizersb 
 
            1.90       1.40     1.86    0.17   6.71 
 
  0.43 – 103.80 
Race/ethnicityc 
   Black 
   Hispanic 
   Other 
 
           -3.10 
            0.61 
           -0.26 
      1.58 
      1.96 
      1.75 
    3.86   
    0.10 
    0.02 
   0.05 
   0.76 
   0.88 
  0.05 
  1.84 
  0.77 
 
0.002 – 1.00 
  0.04 – 84.78 
  0.03 – 23.76 
Genderd             3.50     1.59    4.83   0.03 32.99   1.46 – 745.32
ARV regimen typee 
   Boosted PI 
   Unboosted PI     
   Other 
 
            0.67 
           -1.49 
            1.22 
      1.57 
      2.01 
      1.65 
    0.18 
    0.55 
    0.55 
   0.67 
   0.46 
   0.46 
  1.95 
  0.23 
  3.37 
    
  0.09 – 42.50 
0.004 – 11.45 
  0.13 – 84.80 
Total # of 
medications 
 
            0.01       0.11     0.01    0.91   1.01 
 
  0.81 – 1.26 
Abbreviations: CI = confidence interval, ARV = antiretroviral, PI = protease inhibitor,  
NRTI = nucleoside reverse transcriptase inhibitor 
a Adherence defined as proportion of days covered (PDC) 
Model Chi-Square = 11.89, df = 9, p = 0.22 
Reference categories: b < 80% adherence to mood stabilizers, c white, d male, e nonnucleoside reverse  
     transcriptase inhibitor (NNRTI) 
 
Results of Hypothesis Testing 
Objective Three: To examine the relationship between antiretroviral adherence and 
adherence to psychotropic medications while controlling for race/ethnicity, gender, 
antiretroviral regimen type, and total number of medications. 
 
H011: Among patients using psychotropic medications, there will be no significant 
relationship between adherence to antiretroviral therapy and adherence to 
psychotropic medications while controlling for race/ethnicity, gender, antiretroviral 
regimen type, and total number of medications. 
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Result: Hypothesis is rejected. The odds of being at least 90% adherent to 
combination antiretroviral therapy were 3.37 times higher for those who were at least 
80% adherent to all psychotropic medications. 
 
H012: Among patients taking antidepressants, there will be no significant relationship 
between adherence to antiretroviral therapy and adherence to antidepressants while 
controlling for race/ethnicity, gender, antiretroviral regimen type, and total number of 
medications. 
Result: Hypothesis is rejected. The odds of being at least 90% adherent to 
combination antiretroviral therapy were 4.23 times higher for those who were at least 
80% adherent to antidepressants. 
 
H013: Among patients taking antipsychotics, there will be no significant relationship 
between adherence to antiretroviral therapy and adherence to antipsychotics while 
controlling for race/ethnicity, gender, antiretroviral regimen type, and total number of 
medications. 
Result: Hypothesis not rejected. The odds of being at least 90% adherent to 
combination antiretroviral therapy were not related to adherence with antipsychotics. 
 
H014: Among patients taking mood stabilizers, there will be no significant relationship 
between adherence to antiretroviral therapy and adherence to mood stabilizers while 
controlling for race/ethnicity, gender, antiretroviral regimen type, and total number of 
medications. 
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Result: Hypothesis not rejected. The odds of being at least 90% adherent to 
combination antiretroviral therapy were not related to adherence with mood 
stabilizers. 
 
SUMMARY OF FINDINGS 
A summary of the results of hypothesis testing for Objectives One through 



















Table 3.18 Summary of Results of Hypothesis Testing 
Hypothesis Statistic p-value Outcome
Objective 1 
H01: There will be no significant difference in the 
prevalence of psychotropic medication use among 
HIV-infected patients based on race/ethnicity. 
χ2 (3) = 23.16  <0.001 Rejected
H02: There will be no significant difference in the 
prevalence of psychotropic medication use among 
HIV-infected patients based on gender. 
χ2 (1) = 0.03    0.87 Not 
Rejected 
Objective 2 
H03: There will be no significant difference in the 
rate of adherence to antiretroviral therapy 
between those with and those without 
psychotropic medication use after controlling for 
race/ethnicity, gender, antiretroviral regimen type, 
and total number of medications. 
OR = 0.90; 
95% CI: 0.65 – 1.24 
  0.52 Not 
Rejected 
H04: There will be no significant difference in the 
rate of adherence to antiretroviral therapy based 
on the interaction between psychotropic 
medication use and race/ethnicity. 
F (3) = 2.59   0.05 Rejected
H05: There will be no significant difference in the 
rate of adherence to antiretroviral therapy based 
on the interaction between psychotropic 
medication use and gender. 
F (1) = 0.24   0.62 Not 
Rejected 
H06: There will be no significant difference in the 
rate of adherence to antiretroviral therapy based 
on the interaction between psychotropic 
medication use, race/ethnicity, and gender. 
F (6) = 0.94    0.47 Not 
Rejected 
H07: There will be no significant difference in 
persistence with antiretroviral therapy between 
those with and those without psychotropic 
medication use after controlling for race/ethnicity, 
gender, antiretroviral regimen type, and total 
number of medications. 
b = 4.99, 
t(1310) = 0.61 
  0.54 Not 
Rejected 
H08: There will be no significant difference in 
persistence with antiretroviral therapy based on 
the interaction between psychotropic medication 
use and race/ethnicity. 
F (3) = 2.23    0.08 Not 
Rejected 
H09: There will be no significant difference in 
persistence with antiretroviral therapy based on 
the interaction between psychotropic medication 
use and gender. 
F (1) = 0.001    0.97 Not 
Rejected 
H010: There will be no significant difference in 
persistence with antiretroviral therapy based on 
the interaction between psychotropic medication 
use, race/ethnicity, and gender. 
F (6) = 0.39    0.88 Not 
Rejected 
Abbreviations: OR = odds ratio, CI = confidence interval
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Table 3.18 Summary of Results of Hypothesis Testing - Continued 
Hypothesis Statistic p-value Outcome
Objective 3 
H11: Among patients using psychotropic 
medications, there will be no significant 
relationship between adherence to antiretroviral 
therapy and adherence to psychotropic 
medications while controlling for race/ethnicity, 
gender, antiretroviral regimen type, and total 
number of medications. 
OR = 3.37; 
95 % CI: 1.86 – 6.10 
 <0.001 Rejected
H12: Among patients taking antidepressants, there 
will be no significant relationship between 
adherence to antiretroviral therapy and adherence 
to antidepressants while controlling for 
race/ethnicity, gender, antiretroviral regimen type, 
and total number of medications. 
OR = 4.23;
95% CI: 2.31 – 7.75 
 <0.001 Rejected
H13: Among patients taking antipsychotics, there 
will be no significant relationship between 
adherence to antiretroviral therapy and adherence 
to antipsychotics while controlling for 
race/ethnicity, gender, antiretroviral regimen type, 
and total number of medications. 
OR = 3.33; 
95% CI: 1.21 – 9.19 
 
Note: overall model 
was not significant,    
p = 0.64 
   0.02 Not 
Rejected 
H14: Among patients taking mood stabilizers, 
there will be no significant relationship between 
adherence to antiretroviral therapy and adherence 
to mood stabilizers while controlling for 
race/ethnicity, gender, antiretroviral regimen type, 
and total number of medications. 
OR = 6.71; 
95% CI: 0.43 – 103.80 
   0.17 Not 
Rejected 














This chapter provides a detailed discussion of the results presented in Chapter 
Three.  Results are evaluated in the context of previous studies with consideration for 
the clinical relevance of the findings.  Limitations of the current study are examined, 
and suggestions provided for future research in this area. 
 
STUDY POPULATION 
As discussed in Chapter One, racial and ethnic minorities are 
disproportionately affected by HIV/AIDS, with markedly higher rates of HIV/AIDS 
among blacks and Hispanics as compared to whites.1  The Texas Medicaid data used 
in this study provided a unique opportunity to evaluate the relationship between 
mental disorders and adherence to combination antiretroviral therapy in a racial and 
ethnically diverse population.  Blacks were overrepresented in this sample, 
accounting for 53.1% of the included patients.  This was expected based on 
epidemiologic data showing that blacks are disproportionately affected by HIV/AIDS, 
both in Texas and in the U.S. as a whole.1,2  The proportion of Hispanic patients 
(13.9%) included in this sample is congruent with U.S. population estimates for the 
study time period.3  As predicted based on epidemiologic data on HIV-infected 
patients from Texas,2 the proportion of black females (57.4%) in this sample was 
higher than the proportion of white (38.3%) and Hispanic females (36.1%).   
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PREVALENCE OF MENTAL DISORDERS AMONG HIV-INFECTED PATIENTS 
Results from the National Comorbidity Survey Replication (February 2001 – 
April 2003) indicate that the 12-month prevalence of serious mental disorders in the 
U.S. is around 6.5%.4  In our sample, 501 of 1321 HIV-infected patients (37.9%) met 
the study criteria for having a mental disorder based on use of psychotropic 
medications, which is more than five times the expected rate of serious mental 
disorders in the general population.  Another estimate of the 12-month prevalence of 
mental disorders among U.S. adults, produced by combining data from the 
Epidemiologic Catchment Area (early 1980s) and National Comorbidity Survey 
(early 1990s) studies, puts the one-year rate of mental disorders at 21%.5  This 
estimate includes the prevalence of anxiety disorders in addition to serious mental 
disorders (e.g., major depressive disorder, bipolar disorder, schizophrenia), and may 
be a better comparator for the prevalence rates of mental disorders in the current 
study since the indication for use of antidepressants, which are commonly used to 
treat anxiety disorders, could not be distinguished based on the available data.  
Nonetheless, the 37.9% of HIV-infected patients meeting criteria for a mental 
disorder over a 12-month period in this study is appreciably higher than the 21% 
estimate for the general population.  This is in keeping with data from previous 
studies that showed a higher prevalence of HIV infection among persons suffering 
from serious mental disorders.6-8   
Pence and colleagues used a brief screening instrument to identify probable 
mood, anxiety, and substance abuse disorders in a cohort of 1,125 HIV-positive 
patients presenting to the University of North Carolina Hospitals Infectious Diseases 
Clinic between 2000 and 2002.9  The 12-month prevalence of clinically relevant 
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depression in this population was estimated to be 29% based on patients’ self-
reported symptoms.  This is similar to the rate of antidepressant usage in the current 
study, which was 33.5%.  In a study utilizing New Jersey Medicaid data from 1991 to 
1996, Sambamoorthi and colleagues found the rate of depression among patients with 
HIV/AIDS to be 18%.10  This is notably lower than the rate of antidepressant use seen 
in the current study.  The diagnosis of depression in the Sambamoorthi study was 
based on International Classification of Diseases, Ninth Revision, Clinical 
Modification (ICD-9-CM) codes rather than medication usage data, and only 58% of 
those patients diagnosed with depression were treated with antidepressants. This 
indicates an imperfect correlation between psychotropic medication use and diagnosis 
of a mental disorder.  Taken together, these data show that the estimated prevalence 
of psychiatric disorders among HIV-infected patients may vary due in part to 
differing methods of identifying mental disorders.  However, the rate of mental 
disorders reported among patients with HIV/AIDS is consistently higher than the rate 
of mental disorders in the general population, highlighting the need to understand the 
effects of mental disorders on treatment outcomes for HIV infection.   
Patients meeting criteria for a mental disorder in this study were found to 
differ from those who did not on several of the evaluated baseline characteristics.  
Patients using psychotropic medications were shown to be significantly older than 
those not using psychotropics, though the 2.4 year difference in mean age is unlikely 
to be clinically significant.  The mean age for all patients in this sample was higher 
than expected at 40.2 ± 9.3 years.  This may reflect a tendency of low-income patients 
to seek care for HIV/AIDS later in the disease course following development of 
symptoms, or it may reflect a bias on the part of prescribers to reserve antiretroviral 
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treatment for more mature patients who are perceived as more likely to maintain 
adherence.  In addition to the difference in age, the mean total number of medications 
used at baseline was found to be significantly higher for patients using psychotropics. 
Differences in the total number of medications at baseline were controlled for in 
regression analyses. 
In this study, there was also a variation in the proportion of patients identified 
as having a mental disorder varied based on race/ethnicity, with blacks, Hispanics, 
and patients with a race classified as “other” having a lower proportion of 
psychotropic medication use (32.9%, 37.7%, and 39.0%, respectively) than whites 
(49.3%).  Since both racial/ethnic minorities and persons with serious mental 
disorders are disproportionately affected by HIV/AIDS, the lower rate of mental 
disorders found among minorities in this study was unexpected.  However, given that 
the study definition of a mental disorder was based on psychotropic medication use, 
the lower rate of mental disorders seen among racial/ethnic minorities in this study 
may represent a disparity in the treatment of mental disorders rather than a true 
difference in rate of diagnosis.  Racial/ethnic minorities have poorer access to mental 
health services than whites and are more likely to seek treatment in the general 
healthcare setting than to see a mental health care specialist.5  In data from the 
National Comorbidity Survey, only 11% of Hispanic patients and only 16% of black 
patients with a diagnosable mood disorder received care from a mental health 
specialist.5  Using data from a later (1997-1998), privately-funded, nationally 
representative survey (HealthCare for Communities), Wells and colleagues found that 
black patients were more likely than whites to report an unmet need for alcoholism, 
drug abuse, or mental health treatment, and Hispanic patients were more likely than 
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whites to report delayed care in these areas.11  Access to care may be less of an issue 
in this sample of patients with Medicaid funding, though other barriers to access, such 
availability of providers in rural areas and mistrust of the healthcare system, still 
persist.5   
When they are able to access care, racial/ethnic minorities are less likely than 
whites to receive guideline-based treatment for mental disorders.5  Young and 
colleagues analyzed data from the HealthCare for Communities survey and found that 
blacks were less likely than whites to receive appropriate treatment for depressive and 
anxiety disorders (OR = 0.39, 95% CI: 0.23 – 0.64).12  Hispanics were also less likely 
to receive appropriate treatment in this study, though the difference was not 
statistically significant (OR = 0.58, 95% CI: 0.32 – 1.04).  Utilizing data from the 
National Ambulatory Medical Care Survey, investigators have shown that black and 
Hispanic patients are less likely than whites to receive a prescription for psychotropic 
medications when visiting an outpatient provider for mental health services.13.14  
Studies evaluating samples of Medicaid recipients using data from the 1990s have 
also found variance in psychotropic medication based on race.  Melfi and colleagues 
showed that among a large cohort of Medicaid recipients newly diagnosed with a 
depressive disorder, blacks were half as likely as whites to receive an antidepressant 
in the six months following diagnosis (OR = 0.50, 95% CI: 0.46 – 0.54).15  Kuno and 
Rothbard found that among Medicaid recipients with schizophrenia, blacks were 
significantly more likely than whites to receive long-acting injectable antipsychotics, 
agents which were excluded from analyses in this study.16  Based on these data, 
utilization of psychotropic agents is likely to underestimate the true rate of mental 
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disorders among racial/ethnic minorities, which may explain the lower rates of mental 
disorders seen among minorities in the current study. 
Males and females were almost equally represented in this sample of HIV-
positive patients, with no difference found in the proportion of males and females 
meeting study criteria for a mental disorder. The equal proportion of males and 
females in this study differs from that seen in the general United States population, 
where males with HIV/AIDS outnumber females 3:1.1  However, this discrepancy 
does not appear to be explained by higher rates of mental disorders among females, a 
factor which would be expected to increase the risk of HIV infection.  Female 
patients may be overrepresented in this sample since women are more likely than men 
to be Medicaid recipients.  This difference may also be partially explained by the 
overrepresentation of black subjects in this sample, with black women 
disproportionately affected by HIV/AIDS in Texas.2 
 
RELATIONSHIP BETWEEN MENTAL DISORDERS AND ANTIRETROVIRAL 
ADHERENCE AND PERSISTENCE 
The majority of patients in this sample were using antiretroviral regimens 
containing either an NNRTI (31.5%) or a protease inhibitor boosted with ritonavir 
(28.6%).  Data from recent studies have shown that adequate HIV viral suppression 
can be achieved with lower than 95% adherence to NNRTI-based and ritonavir-
boosted PI-based combination antiretroviral regimens.17-19  However, one of these 
studies demonstrated a dose-response relationship between antiretroviral adherence 
and sustained viral load suppression,18 which indicates that achieving high rates of 
treatment adherence remains a valid goal for HIV-infected patients taking 
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combination antiretroviral therapy.  Furthermore, the ability to maintain persistence 
with antiretroviral therapy is an important factor in treatment success, as life-long 
adherence is required once therapy has been initiated.20 
 
Adherence 
Adherence to combination antiretroviral therapy was found to be low overall 
in this study, with a mean proportion of days covered (PDC) of 39.1% ± 34.6%.  
Studies that evaluated adherence using the Medication Event Monitoring System 
(MEMS) or unannounced pill counts found mean rates of adherence to be closer to 
70%, which is markedly higher than the rate found in this study.17,19,21  Paterson and 
colleagues and Shuter and colleagues both evaluated adherence using MEMS to the 
protease inhibitor components of antiretroviral regimens over a six month time period 
and found adherence rates of 74% and 73%, respectively.19,21  Using unannounced 
pill counts over a median of 9 months, Bangsberg and colleagues found adherence to 
be 70% for all antiretrovirals in an NNRTI-based regimen.17  Nachega and colleagues 
looked at adherence in terms of prescription claims data but used a more liberal 
method than PDC to measure adherence.18  Adherence was defined as the number of 
months with antiretroviral claims submitted divided by the number of months of 
study participation (median 2.2 years).  The overall mean adherence to antiretroviral 
therapy in this study was not given, but it falls in the range of 80-89%, which is more 
than double the rate of adherence found in the current study.   Since the above studies 
linking antiretroviral therapy adherence to HIV outcomes all used alternate 
definitions of adherence, it is difficult to determine how the adherence rate in the 
current study translates into clinical outcomes.  Because no previous studies have 
 83
evaluated adherence to combination antiretroviral therapy based on PDC, it is also 
difficult to determine the degree to which the measurement itself contributed to the 
low adherence rate seen in this study.   
Compared with other commonly used methods for calculating medication 
adherence based on prescription claims data (e.g., medication possession ratio or 
MPR), PDC gives a more conservative estimate of patient adherence, particularly 
when multiple medications within the same class are being considered.22,23  By 
comparing several methods for calculating medication adherence using the same data, 
Choudhry and colleagues showed that interval-based approaches, such as PDC, 
consistently showed lower rates of adherence compared to prescription-based 
approaches, such as MPR, for patients taking multiple related medications (oral 
hypoglycemics).22  Martin and colleagues also showed that in cases of therapeutic 
duplication within a drug class (antipsychotics), adherence measured by MPR was 
85% higher than measurements based on PDC.23  Previous studies using prescription 
claims data to evaluate the relationship between adherence to antidepressants and 
adherence to combination antiretroviral therapy used modified versions of the MPR 
that incorporated use of all antiretroviral medications during the study period to 
calculate adherence.  Both of these studies found higher levels of adherence to 
antiretroviral therapy (72% and 81%) compared with the 39% adherence seen in the 
current study.24,25  Since combination antiretroviral therapy requires therapeutic 
duplication by definition and MPR has a tendency to overestimate adherence in this 
situation, use of PDC for calculating adherence may provide a more accurate 
estimation of actual patient medication-taking behavior. 
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While PDC is more conservative than MPR in general since it avoids double-
counting days of medication coverage, the definition of PDC was made even more 
conservative in this study by requiring patients to have possession of all antiretroviral 
mediations in the initial regimen on a given day to be considered adherent for that 
day.  To achieve perfect adherence, patients were required to have access to each 
antiretroviral medication in the initial regimen for all 365 days of the 12-month 
follow-up.  Use of an average PDC across individual antiretroviral medications was 
considered for this study, though requiring patients to have possession of all 
medications in the regimen on a single day was thought to be more clinically relevant.  
Ideally, HIV-infected patients should take all of their prescribed antiretroviral agents 
at the same time, attacking the virus simultaneously through multiple mechanisms of 
action and reducing the risk of developing resistance to the medications.  It could be 
argued that one year is too long to expect a patient to  remain adherent to an initial 
combination antiretroviral regimen, as some previous studies have reported shorter 
median times to switching among patients initiating antiretroviral therapy.26  
However, the likelihood of switching antiretroviral therapy is almost certainly 
dependent on the type of regimen initiated (factors including pill burden and side 
effect profiles), and data from a recent randomized trial of initial antiretroviral 
treatment strategies found that the median time for switching from a PI-based 
(ritonavir boosted or unboosted) regimen was 18 months compared with 24 months 
for NNRTI-based regimens.27  Therefore, a 12-month period for evaluating adherence 
to an initial antiretroviral regimen in the current study appears to be reasonable.  So, 
while the conservative nature of our adherence measure may have contributed to the 
relatively low rate of adherence rate found in this study, the measure was defined 
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based on parameters deemed to be relevant for patients using combination 
antiretroviral therapy and deserves further study for validation. 
The high degree of variance associated with PDC in this study, as evidenced 
by large standard deviations, decreases the likelihood of finding a statistical 
difference in adherence between groups.  Indeed, adherence to combination 
antiretroviral therapy was not found to be significantly related to the use of 
psychotropic medications indicating the presence of a mental disorder in logistic 
regression analyses controlling for potential confounding factors.  This was true for 
all levels of adherence tested (95%, 90%, 85%, and 80%).  This is in contrast to two 
previous studies that have shown a significant relationship between having symptoms 
of a mental disorder and poorer adherence to antiretroviral medications.28,29  
However, both of these studies used patient self-report to define adherence, which 
may be more subject to bias than prescription claims data.  Also, it is important to 
consider that patients in this study met criteria for a mental disorder through 
psychotropic medication use, and patients treated for a mental disorder may behave 
differently in terms of medication adherence than those who are untreated. 
Results of logistic regression models consistently showed no relationship 
between race/ethnicity or gender and adherence to combination antiretroviral therapy, 
though factorial ANOVA did reveal a significant interaction effect between 
race/ethnicity and use of psychotropic medications on PDC.  Examination of the 
mean PDC for groups separated by race/ethnicity and psychotropic medication use 
showed that the only notable difference was a higher rate of antiretroviral adherence 
among patients using psychotropic medications for those patients with a race/ 
ethnicity defined as “other.”  Given the heterogeneity of the race/ethnicity category 
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“other” and the unexpected higher degree of adherence for patients meeting study 
criteria for a mental disorder, this finding does not appear to have any clinically 
meaningful interpretation.  It is also possible that this significant interaction effect is a 
spurious result brought about by unequal group sizes and population variances 
increasing the risk for a false positive result. 
 
Persistence 
The mean persistence with combination antiretroviral therapy in this study 
was 140.3 ± 137.6 days.  This is shorter than expected based on previous studies that 
evaluated the duration of therapy with an initial combination antiretroviral regimen 
using prospectively collected clinical trial data.  Kirstein and colleagues found that 
the median time to switching or discontinuing an initial combination antiretroviral 
regimen among a large cohort of HIV-infected women was 8 months.26  The short 
duration of persistence in the current study also differs significantly from results of 
the study by MacArthur and colleagues described earlier, in which the median times 
for switching from a PI-based or an NNRTI-based regimen were 18 and 24 months, 
respectively.27  As seen with PDC, the variance in our measure of persistence was 
quite large.  This is expected since the number of days on which patients had 
possession of all antiretroviral agents in the initial regimen was used to calculate both 
adherence and persistence.  The conservative definition of persistence requiring 
patients to have access to all initial antiretroviral medications with no gaps in access 
greater than 60 days may have contributed to the shorter duration of persistence seen 
in this study.  However, definitions of switching in previous studies accounted for 
most changes in therapy, so duration of therapy would not be expected to differ 
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appreciably in the current study.  It is possible that patients enrolled in clinical trials 
may have more motivation to maintain persistence with a particular antiretroviral 
regimen than those identified through prescription claims. 
In contrast to the findings by Walkup and colleagues discussed in Chapter 
One,30 mental illness was not significantly associated with decreased persistence with 
combination antiretroviral therapy in this study.  Walkup and colleagues defined 
persistence based on quarterly use of either PIs or NNRTIs, and expressed their 
results as percentages rather than duration, limiting comparison with results from the 
current study.  In that study, patients with severe affective disorders were less likely 
than patients without serious mental disorders to maintain persistence with 
antiretroviral therapy, though the absolute difference in persistence was modest 
(75.2% versus 78.5%, respectively).  Results of separate regression analyses in the 
Walkup and colleagues study hinted at a possible interaction between mental 
disorders and race in their effects on persistence with antiretroviral therapy, but no 
significant interactions were found using factorial ANOVA in the current study.  
With disparate findings in the limited studies addressing this issue, further research is 
needed to clarify the relationship between mental disorders and persistence with 
combination antiretroviral therapy. 
 
RELATIONSHIP BETWEEN PSYCHOTROPIC MEDICATION ADHERENCE AND 
ADHERENCE TO COMBINATION ANTIRETROVIRAL THERAPY 
Because symptoms of mental disorders may diminish with appropriate 
medication therapy, it is logical to hypothesize that increased adherence to 
psychotropic medications (presumably leading to better symptom control) would 
 88
attenuate the negative effect of mental disorders on adherence to combination 
antiretroviral therapy seen in previous studies.  Both adherence to psychotropic 
medications overall and adherence to antidepressants in particular were found to be 
associated with adherence to antiretroviral medications in this study.  These findings 
are in keeping with data from previous retrospective prescription claims-based studies 
which suggest a link between adherence to antiretroviral therapy and adherence to 
antidepressants among patients diagnosed with a depressive disorder.24,25  While these 
associations suggest that improving adherence to psychotropics, particularly 
antidepressants, may lead to increased adherence with combination antiretroviral 
therapy, a causative relationship cannot be inferred from the current evidence.  
Patients who are adherent to antiretroviral medications may be inherently more likely 
to adhere to prescribed medications in general, or there could be some other 
unrecognized and unaccounted for variable that influences adherence to both 
antiretroviral and psychotropic medications. 
This study attempted to expand on findings from previous studies by 
evaluating the effect of additional psychotropic medication classes on adherence to 
combination antiretroviral therapy.  Unfortunately, group sizes for evaluating these 
effects were small, with only 187 patients identified as users of antipsychotics and 
only 56 patients identified as users of mood stabilizers.  No consistent relationship 
was found between adherence to antipsychotics or mood stabilizers and adherence to 
antiretroviral therapy, though this could have been due to a lack of power to detect 
these effects.  One explanation for the small sample sizes of patients meeting criteria 
for a mental disorder based on use of antipsychotics or mood stabilizers in this study 
may be that prescribers are reluctant to initiate combination antiretroviral therapy in 
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patients with schizophrenia or bipolar disorder due to the association of these 
disorders with medication nonadherence. 
As with adherence to combination antiretroviral therapy, adherence to 
psychotropic medications in this study was found to be low overall, with a mean PDC 
across all classes of psychotropics of 36.7% ± 32.0%.  This low rate of adherence was 
consistent across all drug classes.  Previous studies evaluating the relationship 
between antidepressant adherence and adherence to combination antiretroviral 
therapy found much higher mean rates of antidepressant adherence (77-79%) using 
prescription-based calculations related to the MPR.24,25  Another study using MPR to 
calculate adherence to mood stabilizers among veterans diagnosed with bipolar 
disorder found adherence rates ranging from 76% to 83%.31  In a review of studies 
evaluating adherence to antipsychotics among patients diagnosed with schizophrenia 
using a variety of adherence measures, the mean rate of nonadherence to 
antipsychotics was around 40%.32  This corresponds to an antipsychotic adherence 
rate that is 1.5 times higher than that seen in the current study.  As discussed with 
adherence to antiretroviral medications, use of a conservative measure for calculating 
adherence over a one-year time period may have contributed to the lower rate of 
adherence to psychotropic medications seen in this study as compared to previous 
studies.  Additionally, the calculated adherence for psychotropic medications may 
have been reduced because the index date for evaluating adherence was based upon 
initiation of combination antiretroviral therapy rather than initiation of psychotropics.  
For example, a patient who had 100% adherence to an antidepressant which was 
started six months after starting his index antiretroviral regimen would have a 
calculated PDC of 50% for the antidepressant over the one year follow-up period. 
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SIGNIFICANCE OF FINDINGS 
Our study revealed a high rate of psychotropic medication use among a large 
cohort of patients using combination antiretroviral therapy.  This supports findings 
from previous research that indicate a higher rate of mental disorders among HIV-
infected patients compared to the general population.  The high degree of comorbidity 
between mental disorders and HIV infection underscores the need for an integrated 
treatment approach for addressing these issues.  While we did not find a significant 
relationship between having a having mental disorder and decreased adherence to and 
persistence with antiretroviral therapy in this study, we believe that methodological 
differences may explain why our findings contrast with those from previous studies 
showing these relationships to be significant.  Additional research is needed to help 
inform clinicians about the potential consequences of comorbid mental disorders in 
HIV-infected patients. 
Racial and ethnic differences were observed in the rate of mental disorders 
identified in this population, though not in the expected direction.  It is plausible that 
the lower rate of mental disorders found among ethnic minorities in our study was a 
result of identifying the diagnosis of a mental disorder through medication use in a 
population of patients that has been shown to receive disparate treatment for mental 
disorders.  Because of the important clinical implications that poor identification and 
treatment of mental disorders among racial/ethnic minorities may have for optimizing 
HIV treatment outcomes, the relationships between race/ethnicity, mental disorders, 
and adherence to antiretroviral therapy deserve further study using data with more 
reliable diagnostic identifiers. 
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The low rates of adherence to and persistence with combination antiretroviral 
therapy found in this study emphasize the continuing need for innovative practice 
ideas to enhance compliance with prescribed antiretroviral regimens for all patients.  
Though previous studies used alternate methods of assessing the link between 
antiretroviral medication adherence and HIV outcomes, the significantly lower rate of 
antiretroviral adherence seen in the current study raises concerns about the 
effectiveness of HIV treatment for Texas Medicaid recipients.  Resources directed 
toward improving adherence to combination antiretroviral therapy in this population 
are likely to benefit the greater public health, since suboptimal levels of adherence 
have been associated with the development of drug-resistant HIV strains that can be 
passed on to others.33  Unfortunately, this study did not identify a particular subgroup 
of patients with a greater need for intervention, so efforts to improve antiretroviral 
adherence would probably need to be wide in scope. 
As expected, we found that patients who were adherent to their psychotropic 
medications (including all categories), particularly antidepressants, were more likely 
to be adherent to combination antiretroviral therapy. In subanalyses of psychotropic 
medication categories, we were unable to show a specific effect of adherence to 
antipsychotics or mood stabilizers on antiretroviral adherence, and additional study of 
these relationships using larger sample sizes is needed.  Given the relationship 
between overall psychotropic medication adherence and antiretroviral adherence, 
providers who prescribe combination antiretroviral therapy should ask patients 
regularly about concomitant medications for treatment of mental disorders and assess 
adherence to both therapies.  Education and interventions aimed at improving 
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adherence to antiretroviral therapy among patients with mental disorders should 
incorporate mechanisms to improve adherence to psychotropic medications, as well. 
 
LIMITATIONS 
A significant limitation of this study is the use of psychotropic medications as 
a surrogate marker for the diagnosis of a mental disorder.  Indications for 
psychotropic medication could not be ascertained in this study, and many of these 
medications have indications for conditions other than the targeted mental disorders 
(e.g., anxiety disorders, neuropathic pain, insomnia, and seizure disorders).  We 
attempted to minimize inclusion of patients using psychotropic medications for 
alternative conditions by (1) requiring minimum therapeutic doses for medications 
commonly used in lower doses for insomnia and (2) requiring that anticonvulsants 
commonly used as mood stabilizers be used in combination with other psychotropic 
medications and in the absence of other anticonvulsant agents to be considered as 
mood stabilizers in this study.   
In the study by Yun and colleagues evaluating the relationship between 
adherence to antidepressant therapy and adherence to antiretroviral medications, less 
than half (46%) of the patients who were diagnosed with depression were also 
prescribed antidepressant therapy.24  In a related study by Horberg and colleagues, 
only 36% of the patients identified as having a diagnosis of depression were 
prescribed an SSRI.25  This suggests that using antidepressant prescription claims as a 
marker for a diagnosis of depression is likely to preclude identification of a 
significant number of HIV-infected patients who have been diagnosed with 
depression but who are not currently being treated.  Walkup and colleagues showed 
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that for HIV-infected patients diagnosed with depression, having a prescription for an 
antidepressant agent in the previous month predicted continued use of antiretroviral 
therapy in the current month.34  This finding suggests that adherence behavior may be 
different for patients who are prescribed psychotropic medications compared with the 
general population of HIV-infected individuals with mental disorders.  Therefore, to 
determine the true effect of mental disorders on adherence to combination 
antiretroviral therapy, a more reliable method of identifying the diagnosis of a mental 
disorder than drug utilization is needed. 
Another limitation of our study is the inability to control for several 
potentially important confounding variables.  No information regarding concomitant 
substance use was available for patients included in this study, and previous work has 
shown that drug and alcohol abuse are associated with decreased antiretroviral 
adherence and viral suppression.35,36  Because drug and alcohol abuse are often 
comorbid with serious mental disorders, controlling for these factors is necessary to 
determine if having a mental disorder is an independent risk factor for nonadherence 
to antiretroviral therapy.  Yun and colleagues still found a significant association 
between antiretroviral adherence and adherence to antidepressant therapy even with 
controlling for drug and alcohol use.24  As is often true with prescription claims data, 
no information about hospitalizations or about drugs patients received while 
hospitalized were available for included patients.  Frequent or extended 
hospitalizations could have been factors in the relatively low medication adherence 
rates found in this study. 
Although this study utilized a large database of prescription drug claims to 
identify a sizable cohort of patients using combination antiretroviral therapy, the 
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sample size was small for several of the subgroup analyses.  This led to decreased 
power to detect relationships between adherence to antipsychotic or mood stabilizing 
medications and adherence to antiretrovirals.  Factorial ANOVA is generally robust 
to violations of assumptions with large sample sizes.  However, due to markedly 
unequal group sizes and differences in population variances, there is a concern for 
errors in estimating the significance of interaction effects with factorial ANOVA in 
this study.  Additionally, all patients using antiretroviral medications for treatment of 
HIV/AIDS may not have been identified since the sample was limited to those with 
prescriptions for at least three antiretroviral medications within the three month index 
period.  Patients who filled only part of their prescribed antiretroviral regimen or who 
obtained one or more medications from some other source would have been excluded, 
so results would not be generalizable to these patients.  
Finally, while the association between adherence to combination antiretroviral 
therapy and antidepressant medications seen in this study has potentially important 
clinical implications, we were unable to assess for actual improvements in HIV 
laboratory measures or clinical outcomes for psychotic and mood disorders.  Horberg 
and colleagues found that having a diagnosis of depression was associated with 
decreased odds of achieving HIV viral suppression, but that depressed patients who 
were adherent to SSRIs had a similar likelihood of achieving HIV viral suppression 
as patients without depression.25  This suggests that adherence to psychotropic 
medications among HIV-infected patients receiving combination antiretroviral 
therapy may lead to improved HIV laboratory measures.  Currently, no studies 
evaluating the relationship between adherence to psychotropics and adherence to 
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antiretrovirals have attempted to link adherence to psychotropic medications with 
measures of psychiatric symptom improvement. 
 
AREAS FOR FURTHER RESEARCH 
Future studies using prescription claims data to evaluate the relationship 
between mental disorders and adherence to combination antiretroviral therapy should 
incorporate diagnostic data to avoid misclassifying patients who are not currently 
treated for their mental disorder.  Since many psychotropic medications have multiple 
indications, diagnostic data should help clarify when these medications are being used 
to treat a mental disorder versus some other indication.  Diagnostic data should also 
include information about alcohol and illicit drug abuse to assess whether the effects 
of mental disorders on antiretroviral adherence are independent of the effects of 
commonly comorbid substance use disorders.  Prior work evaluating the relationship 
between psychotropic medication adherence and adherence to antiretroviral therapy 
has focused on use of antidepressants, and our study had relatively small sample sizes 
for addressing this relationship among patients using antipsychotics and mood 
stabilizers.  Therefore, additional research evaluating adherence among HIV-infected 
patients with schizophrenia treated with antipsychotic medications and patients with 
bipolar disorder treated with mood stabilizers is needed. 
Ours is the first study to use proportion of days covered to evaluate adherence 
to combination antiretroviral therapy.  Since we did not have access to laboratory data 
for patients included in this study, additional studies are needed to determine how the 
degree of antiretroviral adherence as measured by PDC relates to HIV outcomes.  
Ideally, outcomes measures for mental disorders would also be included in future 
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studies evaluating the relationship between adherence to psychotropic medications 
and adherence to antiretroviral therapy, though this type of information is not 
typically available retrospectively.  While retrospective evaluations of prescription 
claims data can provide important information about medication adherence patterns 
and factors related to adherence, the nature of these studies does not allow for 
determination of cause and effect.  Prospective studies that evaluate medication 
adherence in combination with rating scales for mental disorders and HIV laboratory 
tests will be needed to confirm the hypothesis that increased adherence to 
psychotropic medications leads to improvements in symptomatology of mental 
disorders, which in turn leads to improved adherence with antiretroviral medications 
and subsequent reductions in viral load and improvements in CD4 lymphocyte count. 
 
CONCLUSIONS 
This study supports findings from previous work showing that the burden of 
mental illness is high among HIV-infected patients.  The finding that white patients 
were more likely than minority patients to meet study criteria for a mental disorder 
based on psychotropic medication use may indicate a disparity in appropriate 
treatment of mental disorders for racial/ethnic minorities with HIV/AIDS.  This 
potential disparity warrants further study, particularly since the rate of mental 
disorders among HIV-infected patients is higher than in the general population and 
racial/ethnic minorities are disproportionately burdened by HIV/AIDS.   
This is the first study to use proportion of days covered to measure 
simultaneous adherence with every drug in the antiretroviral regimen.  This method 
may be particularly useful for evaluating antiretroviral adherence using prescription 
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claims data, as it avoids double-counting days of medication coverage when multiple 
drugs in the same class are used concomitantly.  That said, additional research will be 
needed to test how this measure of adherence relates to HIV outcomes such as viral 
load.  While being treated for a mental disorder was not found to be significantly 
associated with adherence to or persistence with combination antiretroviral therapy in 
this study, limitations in defining mental disorders by psychotropic medication use 
may have affected the results.  Use of diagnostic data to identify patients with mental 
disorders in future studies may give more accurate information about the relationship 
between having a mental disorder and adherence to combination antiretroviral 
therapy.  Adherence to psychotropic medications overall and to antidepressants 
specifically was associated with adherence to antiretroviral therapy in this study.  
This may indicate a relationship between effective treatment for mental disorders and 
antiretroviral adherence among HIV-infected patients, though this relationship 
requires further investigation. 
Adherence to combination antiretroviral therapy is important to achieve 
optimal HIV outcomes and to avoid promoting viral resistance.  Patients with mental 
disorders have been consistently shown to be disproportionately affected by 
HIV/AIDS, and often have difficulty maintaining adherence not only to psychotropic 
medications, but to medications for chronic disease states, as well.  Given the high 
burden of illness and the potential for improved adherence to psychotropic 
medications to lead to improved adherence to antiretroviral therapy, integrated 
treatment for HIV/AIDS and mental disorders should be considered as the standard of 
care. 
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